HTG Molecular Diagnostics (HTGMQ) 10-K 7 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 01, 2019	Jun. 29, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	1,169,987
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,606,012
Entity Public Float			$ 90,728,255

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 8,432,600	$ 9,968,600
Short-term investments available-for-sale, at fair value	22,681,049
Accounts receivable	5,012,678	6,356,268
Inventory, net of allowance of $39,403 and $62,142 at December 31, 2018 and 2017, respectively	1,306,609	1,180,521
Prepaid expenses and other	568,209	443,068
Total current assets	38,001,145	17,948,457
Restricted cash - non-current	3,270,247
Deferred offering costs	59,030	2,953
Deferred MidCap revolving loan costs	67,068
Property and equipment, net	2,373,790	3,304,890
Total assets	43,771,280	21,256,300
Current liabilities:
Accounts payable	1,849,921	2,438,798
Accrued liabilities	3,358,465	3,746,786
Contract liabilities - current	332,711	665,882
NuvoGen obligation - current	1,290,234	496,442
Growth Term Loan payable - net of discount and debt issuance costs		5,793,599
Other current liabilities	186,043	200,460
Total current liabilities	7,017,374	13,341,967
NuvoGen obligation - non-current, net of discount	5,702,519	7,520,913
Convertible note, related party - net of debt issuance costs	2,974,213	2,960,760
MidCap Term Loan payable - net of discount and debt issuance costs	6,704,641
Other non-current liabilities	280,471	492,197
Total liabilities	22,679,218	24,315,837
Commitments and Contingencies (Note 14)
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2018 and December 31, 2017, 28,585,449 shares issued and outstanding at December 31, 2018 and 13,929,763 shares issued and outstanding at December 31, 2017	28,585	13,929
Additional paid-in-capital	172,086,909	131,492,595
Accumulated other comprehensive loss	(3,453)
Accumulated deficit	(151,019,979)	(134,566,061)
Total stockholders’ equity (deficit)	21,092,062	(3,059,537)
Total liabilities and stockholders' equity (deficit)	$ 43,771,280	$ 21,256,300

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Inventory net allowance	$ 39,403	$ 62,142
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	28,585,449	13,929,763
Common stock, shares outstanding	28,585,449	13,929,763

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue:
Total revenue	$ 21,503,894	$ 14,759,567
Operating expenses:
Cost of product and product-related services revenue	$ 5,090,475	$ 4,971,806
Type of Cost, Good or Service [Extensible List]	htgm:ProductAndProductRelatedServicesMember	htgm:ProductAndProductRelatedServicesMember
Selling, general and administrative	$ 19,974,616	$ 17,513,742
Research and development	12,598,034	9,996,627
Total operating expenses	37,663,125	32,482,175
Operating loss	(16,159,231)	(17,722,608)
Other income (expense):
Interest expense	(901,820)	(1,307,674)
Interest income	715,723	73,186
Loss on extinguishment of Growth Term Loan	(105,064)
Total other income (expense)	(291,161)	(1,234,488)
Net loss before income taxes	(16,450,392)	(18,957,096)
Provision for income taxes	3,526	2,921
Net loss	$ (16,453,918)	$ (18,960,017)
Net loss per share, basic and diluted	$ (0.60)	$ (1.79)
Shares used in computing net loss per share, basic and diluted	27,523,463	10,597,318
Product and Product-related Services
Revenue:
Total revenue	$ 9,121,390	$ 6,797,255
Collaborative Development Services
Revenue:
Total revenue	$ 12,382,504	$ 7,962,312

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (16,453,918)	$ (18,960,017)
Other comprehensive income (loss), net of tax effect:
Unrealized gain (loss) on short-term investments	(2,308)	1,090
Foreign currency translation adjustment	(1,145)
Total other comprehensive income (loss)	(3,453)	1,090
Comprehensive loss	$ (16,457,371)	$ (18,958,927)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Total	ATM Offering	Underwritten Public Offering	Common Stock	Common StockATM Offering	Common StockUnderwritten Public Offering	Additional Paid-In Capital	Additional Paid-In CapitalATM Offering	Additional Paid-In CapitalUnderwritten Public Offering	Treasury Stock	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Dec. 31, 2016	$ (5,592,862)			$ 7,938			$ 110,081,334			$ (75,000)	$ (1,090)	$ (115,606,044)
Balance, shares at Dec. 31, 2016				7,938,571
Exercise of stock options	112,138			$ 42			112,096
Exercise of stock options, shares				41,815
Stock-based compensation expense	1,376,633						1,376,633
Release of restricted stock awards	336			$ 336
Release of restricted stock awards, shares				336,333
Stock issued under stock purchase plan	$ 325,667			$ 141			325,526
Stock issued under stock purchase plan, shares	61,141			141,082
Issuance of common stock		$ 19,677,478			$ 5,472			$ 19,672,006
Issuance of common stock, shares					5,471,962
Retirement of Treasury shares							(75,000)			$ 75,000
Net loss	$ (18,960,017)											(18,960,017)
Unrealized gain (loss) on short-term investments	1,090										1,090
Balance at Dec. 31, 2017	(3,059,537)			$ 13,929			131,492,595					(134,566,061)
Balance, shares at Dec. 31, 2017				13,929,763
Exercise of stock options	316,767			$ 145			316,622
Exercise of stock options, shares				144,645
Stock-based compensation expense	1,887,764						1,887,764
Release of restricted stock awards	291			$ 291
Release of restricted stock awards, shares				291,010
Net share settlement of restricted stock awards	(150,748)			$ (39)			(150,709)
Net share settlement of restricted stock awards, shares				(38,582)
Stock issued under stock purchase plan	$ 199,874			$ 82			199,792
Stock issued under stock purchase plan, shares	2,304			82,261
Issuance of common stock		$ 556,706	$ 37,724,316		$ 262	$ 13,915		$ 556,444	$ 37,710,401
Issuance of common stock, shares					261,352	13,915,000
Issuance of common stock warrants in connection with MidCapTerm Loan	$ 74,000						74,000
Net loss	(16,453,918)											(16,453,918)
Unrealized gain (loss) on short-term investments	(2,308)										(2,308)
Foreign currency translation adjustment	(1,145)										(1,145)
Balance at Dec. 31, 2018	$ 21,092,062			$ 28,585			$ 172,086,909				$ (3,453)	$ (151,019,979)
Balance, shares at Dec. 31, 2018				28,585,449

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement Of Stockholders Equity [Abstract]
At the market offering, issuance costs	$ 17,000	$ 800,000
Public offering issuance costs	$ 2,600,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating activities
Net loss	$ (16,453,918)	$ (18,960,017)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,468,121	1,241,873
Accretion of discount on NuvoGen obligation	(12,480)	195,248
Provision for excess inventory	83,218	366,963
Amortization of Growth Term Loan discount and issuance costs	62,951	404,462
Loss on extinguishment of Growth Term Loan	105,064
Amortization of QNAH Convertible Note issuance costs	13,453	1,269
Amortization of MidCap Credit Facility discount and issuance costs	133,963
Stock-based compensation expense	1,888,055	1,376,969
Employee stock purchase plan expense	58,959	59,118
Accretion of incentive from landlord	(142,000)	(142,000)
Accrued interest on available-for-sale securities investments	(412,436)
Loss on disposal of assets	8,104	81,539
Changes in operating assets and liabilities:
Accounts receivable	1,332,030	(4,978,827)
Inventory	(171,909)	77,176
Prepaid expenses and other	(113,581)	(3,749)
Deferred offering costs	2,953	49,630
Accounts payable	(150,176)	1,225,954
Accrued liabilities	(447,351)	2,076,500
Contract liabilities	(426,938)	355,584
Net cash used in operating activities	(13,173,918)	(16,572,308)
Investing activities
Purchase of property and equipment	(949,514)	(1,020,531)
Sales, redemptions and maturities of available-for-sale securities	31,700,000	4,300,000
Purchase of available-for-sale securities	(53,970,921)
Net cash (used in) provided by investing activities	(23,220,435)	3,279,469
Financing activities
Proceeds from MidCap Credit Facility	7,000,000
MidCap Credit Facility lender fees	(422,390)
Payments on Growth Term Loan	(1,684,626)	(6,389,782)
Payments for extinguishment of Growth Term Loan	(4,276,988)
Proceeds from public offering, net of underwriting discounts, commissions and costs of $2.6 million	37,724,316	(231,476)
Proceeds from ATM Offering, net	556,706	19,908,954
Proceeds from issuance of convertible note to QNAH, a related party		3,000,000
QNAH Convertible Note financing costs		(40,509)
Payments on NuvoGen obligation	(1,012,122)	(800,000)
Payments on capital leases	(62,085)	(69,142)
Proceeds from exercise of stock options	316,767	112,138
Taxes paid for net share settlement of restricted stock awards	140,915
Proceeds from shares purchased under stock purchase plans		266,549
Payment of deferred offering costs	(150,748)	(2,952)
Net cash provided by financing activities	38,129,745	15,753,780
Effect of exchange rates on cash	(1,145)
Increase in cash, cash equivalents and restricted cash	1,734,247	2,460,941
Cash and cash equivalents at beginning of year	9,968,600	7,507,659
Cash, cash equivalents and restricted cash at end of year	11,702,847	9,968,600
Supplemental disclosure of noncash investing and financing activities
Fixed asset purchases payable and accrued at period end	39,265	477,966
Carrying value of demonstration units transferred from property and equipment to inventory	49,245	113,607
Equipment purchased through capital lease	71,709
Debt issuance costs payable and accrued at period end	59,030
MidCap Term Loan fees and warrant discount	389,000
Retirement of treasury stock		75,000
Supplemental cash flow information
Cash paid for interest	553,070	698,065
Cash paid for taxes	$ 3,545	$ 1,967

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)
Statement Of Cash Flows [Abstract]
Underwriting discounts, commissions and costs	$ 2.6

Description of Business, Basis

Description of Business, Basis of Presentation and Principles of Consolidation	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Description of Business, Basis of Presentation and Principles of Consolidation	Note 1. Description of Business, Basis of Presentation and Principles of Consolidation HTG Molecular Diagnostics, Inc. (the “Company”) is a provider of instruments, reagents and services for molecular profiling applications. The Company derives revenue from sales of its HTG EdgeSeq automation system and integrated next-generation sequencing-based HTG EdgeSeq assays, from services including sample processing and custom research use only (“RUO”) assay development and from collaborative development services. The Company operates in one segment and its customers are located primarily in the United States and Europe. For the year ended December 31, 2018, approximately 69% of the Company’s revenue was generated from sales originated by customers located outside of the United States, compared with 71% for the year ended December 31, 2017. Approximately 84% and 76% of the sales to customers located outside of the United States resulted from collaborative development services revenue generated from the Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”), with QIAGEN Manchester Limited (“QML”), a wholly owned subsidiary of QIAGEN N.V. (See Note 16), for the years ended December 31, 2018 and 2017, respectively. Basis of Presentation The consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Principles of Consolidation The Company formed a French subsidiary, HTG Molecular Diagnostics France SARL (“HTG France”), in November 2018. The consolidated financial statements include the accounts of the Company and this wholly owned subsidiary after elimination of intercompany transactions and balances as of December 31, 2018. Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, bonus accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with financial institutions, commercial paper, money market instruments and high credit quality corporate debt securities purchased with a term of three months or less. Accounts Receivable Accounts receivable represent valid claims against debtors. Management reviews accounts receivable regularly to determine, using the specific identification method, if any receivable amounts will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value. Investments The Company classifies its debt securities as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive loss, net of tax. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, are included in other income (expense) within the accompanying consolidated statements of operations. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Interest earned on all securities is included in other income (expense) within the accompanying consolidated statements of operations. Investments in securities with maturities of less than one year, or where management’s intent is to use the investments to fund current operations, or to make them available for current operations, are classified as short-term investments. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are charged against other income (expense). Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts shown in the accompanying consolidated statements of cash flows. December 31, 2018 Cash and cash equivalents $ 8,432,600 Restricted cash - non-current 3,270,247 Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 11,702,847 Amounts included in restricted cash represent those required to be set aside in escrow under the terms of the MidCap Term Loan (see Note 8) to collateralize the payment that will be due upon maturity of the QNAH Convertible Note (see Note 16). The amounts will be released to the Company upon subsequent delivery of subordination documents for the QNAH Convertible Note to MidCap or conversion of the QNAH Convertible Note. If neither occurs, the amounts will be applied by the escrow agent to repay in full the QNAH Convertible Note at maturity (or in connection with a prepayment at the direction of the Company) subject to the terms of the MidCap Term Loan. Contract Assets Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer, for which rights to payment are conditional upon something other than the passage of time. Fair Value of Financial Instruments Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date. Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the MidCap Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt securities with similar terms and risk characteristics. In October 2017, the Company received $3.0 million in gross proceeds from, and issued a subordinated convertible promissory note (the “QNAH Convertible Note”) in that principal amount to, QIAGEN North American Holdings, Inc. (“QNAH”). As of December 31, 2018, the estimated aggregate fair value of the QNAH Convertible Note is approximately $3.1 million, based on a discounted cash flow approach and utilizing an option pricing model to value the conversion feature, with key assumptions including expected volatility, discount rates, term and risk-free rates. The NuvoGen obligation is an obligation relating to an asset purchase transaction with a then-common stockholder of the Company. As of December 31, 2018, the estimated aggregate fair value of the NuvoGen obligation is approximately $6.0 million, determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates. The estimated fair values of the QNAH Convertible Note and the NuvoGen obligation represent Level 3 measurements. Inventory, net Inventory, consisting of raw materials, work in process and finished goods, is stated at the lower of cost (first-in, first-out) or net realizable value. Cost is determined using a standard cost system, whereby the standard costs are updated periodically to reflect current costs and net realizable value represents the lower of replacement cost or estimated net realizable value. The Company reserves or writes down its inventory for estimated obsolescence or inventory in excess of reasonably expected near term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. The period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may need to be extended beyond that period. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent rental agreement with the Company after evaluating the product for one year, the equipment is returned to the Company or the customer is allowed to continue use of the equipment, in which case the equipment is written off to selling, general and administrative expense in the accompanying consolidated statements of operations. HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Finished goods inventory under evaluation as of December 31, 2018 was $143,271 compared to $53,365 as of December 31, 2017. Property and Equipment, net Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method. Equipment used in the field is amortized using the straight-line method over the lesser of the period of the related reagent rental or collaborative development services agreement where applicable or the estimated useful life. Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life. Certain leasehold improvements constructed by the landlord of the Company’s Tucson, AZ facilities as an incentive for the Company to extend its leases are included in leasehold improvements in the consolidated balance sheets as of December 31, 2018. The total cost of the improvements constructed by the landlord of $710,000 was capitalized when construction was completed in February 2016 and is being amortized over the remaining term of the lease agreement. The incentive of $710,000 has been recognized as deferred rent within other current liabilities and other liabilities on the consolidated balance sheets and is being accreted over the lease term as a reduction of rent expense (see Note 14). Costs incurred in the development and installation of software for internal use and in the development of the Company’s website are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed). Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to the estimated undiscounted future cash flows expected to be generated by the asset group. If the carrying amount of an asset group exceeds its estimated future cash flow, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Although the Company has accumulated losses since inception, the Company believes the future cash flows will be sufficient to exceed the carrying value of the Company’s long-lived assets. There were no impairments of long-lived assets during the years ended December 31, 2018 and 2017. Debt Issuance Costs and Debt Discounts Costs incurred to issue non-revolving debt instruments are recognized as a reduction to the related debt balance in the accompanying consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Costs incurred to issue revolving debt instruments are deferred as an asset in the accompanying consolidated balance sheets and amortized on a straight-line basis to interest expense over the term of the revolving commitment . Deferred Offering Costs Deferred offering costs represent legal and other direct costs related to planned future stock offering transactions. Deferred offering costs of $59,030 included as non-current assets in the accompanying consolidated balance sheets represent legal costs incurred during the year ended December 31, 2018 by the Company in contemplation of the issuance of additional shares in a future financing transaction. There were deferred offering costs of $2,953 included in the accompanying consolidated balance sheets as of December 31, 2017. Should the planned stock offering transactions prove to be unsuccessful, these deferred offering costs, as well as any additional expenses to be incurred, will be charged to selling, general and administrative expense in the consolidated statements of operations. Contract Liabilities Contract liabilities represent cash receipts for products or services to be delivered in future periods, including up-front fees received relating to custom RUO assay design and sample processing services and collaboration development services. When products or services are delivered to customers, contract liabilities are recognized as earned. Up-front fees received for custom RUO assay design or collaborative development services are recognized over time based on the costs incurred to date compared to total expected costs as design or development procedures are completed and outputs are produced. Revenue Recognition The Company adopted the Financial Accounting Standards Board (“FASB”) new revenue standard, Accounting Standards Codification 606, Revenue from Contracts with Customers For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. The Company has made a policy election to exclude from the measurement of the transaction price all taxes assessed by a government authority that are both imposed on and concurrent with a specific revenue producing transaction and collected by the Company from a customer. Such taxes may include but are not limited to sales, use, value added and certain excise taxes. See Note 9 for additional discussion of the Company’s revenue recognition policies. Product Warranty The Company generally provides a one-year warranty on its HTG EdgeSeq systems covering the performance of system hardware and software in conformance with customer specifications under normal use and protecting against defects in materials and workmanship. The Company may, at its option, replace, repair or exchange products covered under valid warranty claims. A provision for estimated warranty costs is recognized at the time of sale, through cost of product and product-related services revenue, based upon recent historical experience and other relevant information as it becomes available. The Company continuously assesses the adequacy of its product warranty accrual by reviewing actual claims and adjusts the provision as needed. Research and Development Expenses Research and development expenses represent costs incurred internally for research and development activities and costs incurred externally to fund research activities. These costs include those generated through research and development efforts for the improvement and expansion of the Company’s proprietary technology and product offerings as well as those related to third-party collaborative development agreements, for which related revenue is included in collaborative development services revenue in the accompanying consolidated statements of operations. See for further discussion of the development costs associated with collaborative development services agreements included in research and development expense as compared to cost of revenue in the accompanying consolidated statements of operations. Advertising All costs associated with advertising and promotions are expensed as incurred. Advertising expense was $110,591 and $245 for the years ended December 31, 2018 and 2017, respectively, and is included as a component of selling, general and administrative expenses on the accompanying consolidated statements of operations. Stock-based Compensation The Company incurs stock-based compensation expense relating to grants under its equity incentive plans of restricted stock units (“RSUs”) and stock options to employees, consultants and non-employee directors, and stock purchase rights granted under its employee stock purchase plan (“ESPP”). The Company recognizes expense for stock-based awards to employees and non-employee directors based on the fair value of awards on the date of grant. The fair value of RSUs is based on the quoted market price of the Company’s common stock on the date of grant. The fair value of ESPP rights and stock options granted pursuant to the Company’s equity incentive plans is estimated on the date of grant using the Black-Scholes option pricing model. The determination of the fair value utilizing the Black-Scholes option pricing model is affected by the fair value of the Company’s stock price and several assumptions, including volatility, expected term, risk-free interest rate, and dividend yield. Generally, these assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. The Company elected to change its policy surrounding forfeitures of equity awards with the adoption of the guidance in ASU No. 2016-09 on January 1, 2017. The Company no longer estimates the number of awards expected to be forfeited but instead accounts for such forfeitures as they occur. For stock-based awards to consultants, the fair value of the stock-based award is used to measure the transaction, as the Company believes this to be a more reliable measure of fair value than the services received. The fair value of each award is remeasured at each measurement date until performance by the nonemployee is complete. Stock-based compensation to nonemployees is recognized as expense over the requisite service period, which is generally the vesting period for awards, on a straight-line basis. Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts and tax base of assets and liabilities using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established against net deferred tax assets for the uncertainty it presents of our ability to use the net deferred tax assets, in this case, primarily carryforwards of net operating tax losses and research and development tax credits. In assessing the realizability of net deferred tax assets we have assessed the likelihood that net deferred tax assets will be recovered from future taxable income, and to the extent that recovery is not “more likely than not” or there is an insufficient history of operating profits, a valuation allowance is established. We record the valuation allowance in the period we determine that it is not more likely than not that net deferred tax assets will be realized. For the years ended December 31, 2018 and 2017, we have provided a full valuation allowance for all net deferred tax assets due to their current realization being considered remote in the near term. Uncertain tax positions taken or expected to be taken in a tax return are accounted for using the more likely than not threshold for financial statement recognition and measurement. The Tax Cuts and Jobs Act (the “Tax Act”), which was signed into law on December 22, 2017, significantly revised the Internal Revenue Code of 1986, as amended (the “IRC”). For further information as to its impact on our financial statements see “Note 15. Income Taxes” in Part II, Item 8, Notes to Financial Statements. Foreign Currency Translation and Foreign Currency Transactions The Company has assets and liabilities, including accounts receivable and accounts payable, which are denominated in currencies other than its functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency gain (loss) within the consolidated statements of operations. Adjustments resulting from translating foreign functional currency financial statements of the Company’s wholly owned subsidiary into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the accompanying consolidated statements of stockholder’s equity (deficit). Comprehensive Loss Comprehensive loss includes certain changes in equity that are excluded from net loss. Specifically, unrealized gains and losses on short and long-term available-for-sale investments and adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in comprehensive loss. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom RUO panel design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The top three customers accounted for 58%, 10% and 9% of the Company’s revenue for the year ended December 31, 2018, compared with 54%, 8% and 6% for the year ended December 31, 2017. The largest three customers accounted for approximately 44%, 27%, and 11% of the Company’s net accounts receivable as of December 31, 2018. The accounts receivable primarily relate to sample processing services performed for two biopharmaceutical company customers and work performed under the Company’s Governing Agreement with QML. The largest two customers accounted for approximately 66% and 11% of the Company’s net accounts receivable at December 31, 2017. Three vendors accounted for 24%, 14% and 11% of the Company’s accounts payable as of December 31, 2018 primarily related to the Company’s collaborative development services programs compared to 23%, 17% and 15% of the Company’s accounts payable at December 31, 2017. The Company currently relies on a single supplier to supply a subcomponent used in the HTG EdgeSeq processors. A loss of this supplier could significantly delay the delivery of products, which in turn would materially affect the Company’s ability to generate revenue. Recently Adopted Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In March 2016, the FASB issued ASU No. 2016-08, Revenue Recognition: Clarifying the new Revenue Standard’s Principal-Versus-Agent Guidance In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients. The new revenue standard and the standards that amend it were effective for public entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company adopted ASC 606 as of January 1, 2018 using the full retrospective approach. The adoption of ASC 606 did not have a material impact on 2017 revenue recognition or on opening equity, as the timing and measurement of revenue recognition is materially the same for the Company as under ASC 605, Revenue Recognition In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting New Accounting Pronouncements The following are new FASB ASUs that had not been adopted by the Company as of December 31, 2018, and are grouped by their respective effective dates: January 1, 2019 In February 2016, the FASB issued ASU No. 2016-02, Leases, In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting January 1, 2020 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In November 2018, the FASB issued ASU No. 2018-18, which amended ASC 808, Collaborative Arrangements Revenue from Contracts with Customers .

Inventory

Inventory	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of allowance, consisted of the following as of the date indicated: December 31, 2018 2017 Raw materials $ 892,631 $ 984,328 Work in process 168,937 66,314 Finished goods 284,444 192,021 Total gross inventory 1,346,012 1,242,663 Less inventory allowance (39,403 ) (62,142 ) $ 1,306,609 $ 1,180,521 The reserve for shrinkage and excess inventory was $39,403 and $62,142 as of December 31, 2018 and 2017, respectively. For the year ended December 31, 2018, the Company recorded a net decrease in the inventory reserve of $22,739, compared to a net decrease of $208,165 for the year ended December 31, 2017, to adjust for estimated shrinkage and obsolescence. For the years ended December 31, 2018 and 2017, the Company recorded adjustments to the provision for excess inventory of $83,218 and $366,963, respectively. Adjustments in these periods to the allowance for estimated shrinkage, obsolescence and excess inventory have been included in cost of product and product-related services revenue in the accompanying consolidated statements of operations.

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value	Note 4. Fair Value Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy, based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at December 31, 2018 and 2017, respectively, in the fair value hierarchy: Balance at December 31, 2018 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 6,923,255 $ 998,400 $ — $ 7,921,655 Investments available-for-sale at fair value U.S. government obligations 6,031,515 — — 6,031,515 Corporate debt securities — 16,649,534 — 16,649,534 Total $ 12,954,770 $ 17,647,934 $ — $ 30,602,704 Balance at December 31, 2017 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 8,521,054 $ — $ — $ 8,521,054 Total $ 8,521,054 $ — $ — $ 8,521,054 There were no other financial instruments subject to fair value measurement on a recurring basis. Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the years ended December 31, 2018 and 2017. Level 1 instruments include investments in money market funds, U.S. Treasuries and U.S. government agency obligations. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include corporate debt securities and commercial paper. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g. indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. Fair values of these assets and liabilities are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for either of the years ended December 31, 2018 or 2017 and did not have any Level 3 financial assets or liabilities during either of these periods.

Available for Sale Securities

Available for Sale Securities	12 Months Ended
	Dec. 31, 2018
Investments Debt And Equity Securities [Abstract]
Available-for-Sale Securities	Note 5. Available-for-Sale Securities The Company’s portfolio of available-for-sale securities consists of U.S. Treasuries and high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities at December 31, 2018: December 31, 2018 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 6,032,844 $ — $ (1,329 ) $ 6,031,515 Corporate debt securities 16,650,513 — (979 ) 16,649,534 Total available-for-sale securities $ 22,683,357 $ — $ (2,308 ) $ 22,681,049 The Company had no available-for-sale securities at December 31, 2017. The net adjustment to unrealized holding gains (losses) on available-for-sale securities, net of tax in other comprehensive income totaled $(2,308) and $1,090 for the years ended December 31, 2018 and 2017, respectively. Contractual maturities of debt investment securities at December 31, 2018 are shown below. Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. Under 1 Year 1 to 2 Years Total U.S. Treasury securities $ 6,031,515 $ — $ 6,031,515 Corporate debt securities 16,649,534 — 16,649,534 Total available-for-sale securities $ 22,681,049 $ — $ 22,681,049 The following table shows the gross unrealized losses and fair values of the Company’s investments that have unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of December 31, 2018: Under 1 Year 1 to 2 Years Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses U.S. Treasury securities $ 6,031,515 $ (1,329 ) $ — $ — $ 6,031,515 $ (1,329 ) Corporate debt securities 1,201,308 (979 ) — — 1,201,308 (979 ) Total available-for-sale securities with unrealized losses $ 7,232,823 $ (2,308 ) $ — $ — $ 7,232,823 $ (2,308 ) For debt securities, the Company determines whether it intends to sell or if it is more likely than not that it will be required to sell impaired securities. This determination considers current and forecasted liquidity requirements, regulatory and capital requirements and securities portfolio management. For all impaired debt securities for which there was no intent or expected requirement to sell, the evaluation considers all available evidence to assess whether it is likely the amortized cost value will be recovered. The Company conducts a regular assessment of its debt securities with unrealized losses to determine whether securities have other-than-temporary impairment considering, among other factors, the nature of the securities, credit rating or financial condition of the issuer, the extent and duration of the unrealized loss, expected cash flows of underlying collateral, market conditions and whether the Company intends to sell or it is more likely than not that the Company will be required to sell the debt securities. The Company did not have any other-than-temporary impairment in its available-for-sale securities at December 31, 2018.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment, net consists of the following: December 31, 2018 2017 Furniture & fixtures $ 791,973 $ 582,007 Leasehold improvements 1,930,300 1,863,698 Equipment used in manufacturing 2,297,797 1,963,558 Equipment used in research & development 1,456,954 1,328,556 Equipment used in the field 125,253 130,552 Software 373,683 373,683 Construction in progress 19,246 255,641 6,995,206 6,497,695 Less: accumulated depreciation and amortization (4,621,416 ) (3,192,805 ) $ 2,373,790 $ 3,304,890 Depreciation and leasehold improvement amortization expense was $1,468,121 for the year ended December 31, 2018, and $1,241,873 for the year ended December 31, 2017.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consist of the following: December 31, 2018 2017 Accrued employee bonuses $ 2,150,418 $ 3,049,109 Payroll and employee benefit accruals 698,969 369,275 Accrued professional fees 60,400 101,150 Accrued interest 156,492 45,544 Other accrued liabilities 292,186 181,708 $ 3,358,465 $ 3,746,786

Debt Obligations

Debt Obligations	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Debt Obligations	Note 8. Debt Obligations. Growth Term Loan In August 2014, the Company entered into a Loan and Security Agreement (the “Growth Term Loan”) with a syndicate of two lending institutions, Oxford Finance LLC and Silicon Valley Bank, which was amended in August 2015 and June 2016. The first tranche of the Growth Term Loan (“Growth Term Loan A”) of $11.0 million was funded in August 2014. The second tranche of $5.0 million (“Growth Term Loan B”) was funded in March 2016. With the August 2015 amendment, the interest-only payment period for the Growth Term Loan was extended until April 1, 2016. Following the interest-only payment period, the Company became obligated to make equal monthly payments of principal and interest amortized over the remaining term of the loan for all funds drawn under the Growth Term Loan. Growth Term Loan A and B bore interest at fixed rates of 8.5% and 8.75% per annum, respectively, and were scheduled to mature in September 2018. The amended agreement also included a prepayment fee of 1% of the principal amount repaid if the Growth Term Loan was repaid after the second anniversary of the August 2015 amendment and prior to maturity. The Company recognized approximately $629,777 of debt discount associated with the Growth Term Loan A and Growth Term Loan B in the accompanying consolidated balance sheets as of December 31, 2017, resulting from unamortized direct loan costs, warrant allocation and the final payment fee. The debt discount was being amortized to interest expense using the effective interest method, over the term of the related Growth Term Loan tranche. The aggregate amortization of debt discount associated with the Growth Term Loan was approximately $62,951 and $404,462 for the years ended December 31, 2018 and 2017, respectively. Extinguishment of Growth Term Loan upon MidCap Credit Facility Closing In March 2018, the Company repaid all principal and interest amounts outstanding under the Growth Term Loan in an aggregate amount equal to approximately $4.3 million, including collateral agent legal fees and prepayment fees. The repayment was funded with net proceeds from the MidCap Credit Facility (see description of the MidCap Credit Facility below). As a result of the repayment, the Company recorded a loss on extinguishment of the Growth Term Loan of $105,064, including remaining unamortized discounts of $67,272 and prepayment and other Growth Term Loan lender fees in the accompanying consolidated statements of operations for the year ended December 31, 2018. MidCap Credit Facility On March 26, 2018 (the “MidCap Closing Date”), the Company entered into a Credit and Security Agreement (Term Loan) (the “MidCap Term Loan”) and a Credit and Security Agreement (Revolving Loan) (the “MidCap Revolving Loan” and together with the MidCap Term Loan, the “MidCap Credit Facility”) with MidCap Financial Trust, as agent. MidCap Financial Trust subsequently assigned its rights and obligations as agent to MidCap Funding IV Trust. The MidCap Term Loan provides a secured term loan facility in an aggregate principal amount of up to $20.0 million. The Company borrowed the first advance of $7.0 million (“MidCap Tranche 1”) on the MidCap Closing Date. Under the terms of the MidCap Term Loan, the second advance of $13.0 million (“MidCap Tranche 2”) will be available to the Company on or before September 30, 2019, subject to the Company’s satisfaction of certain conditions described in the MidCap Term Loan, including (a) the Company achieving the first commercial sale of an FDA-approved diagnostic assay utilizing next generation sequencing under its Governing Agreement with QML, and (b) delivery of subordination documents with respect to the QNAH Convertible Note (or the satisfaction of alternative arrangements as provided in the MidCap Term Loan, as described below). MidCap Tranche 1 was used to repay in full all outstanding amounts and fees due under the Growth Term Loan. The proceeds remaining from MidCap Tranche 1 and, if borrowed, the proceeds from MidCap Tranche 2, are expected to be used for working capital and general corporate purposes. MidCap Tranche 1, and if borrowed, MidCap Tranche 2, each bear interest at a floating rate equal to 7.25% per annum, plus the greater of (i) 1.25% or (ii) the one-month LIBOR. Interest on each term loan advance is due and payable monthly in arrears and was calculated at a rate of 9.6% for interest accrued as of December 31, 2018. Principal on each term loan advance is payable in 36 equal monthly installments beginning April 1, 2020 until paid in full on March 1, 2023. Prepayments of the term loans under the MidCap Term Loan, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the MidCap Closing Date, 2.0% of principal prepaid if prepayment occurs after the first anniversary of the MidCap Closing Date but on or prior to the second anniversary of the MidCap Closing Date, and 1.0% of principal prepaid if prepayment occurs after the second anniversary of the MidCap Closing Date and prior to or on the third anniversary of the MidCap Closing Date. In connection with execution of the MidCap Term Loan, the Company paid MidCap a $100,000 origination fee. Upon termination of the MidCap Term Loan, the Company is required to pay an exit fee equal to 4.50% of the principal amount of all term loans advanced to the Company under the MidCap Term Loan. The MidCap Term Loan also required that the Company deliver subordination documents with respect to the QNAH Convertible Note, or that the QNAH Convertible Note otherwise be converted or prepaid, on or before June 30, 2018, and required the Company to deposit approximately $3.3 million into an escrow account by July 15, 2018 if neither event occurred by such date. As neither event occurred prior to June 30, 2018, the Company deposited approximately $3.3 million into an escrow account on July 11, 2018. Such escrowed funds will be released to the Company upon subsequent delivery of the requisite subordination documents or conversion of the QNAH Convertible Note. If neither delivery of the subordination documents or conversion of the QNAH Convertible Note occurs, such funds will be applied by the escrow agent to repay in full the QNAH Convertible Note at maturity (or in connection with a prepayment at the direction of the Company), subject to (i) the Company having drawn MidCap Tranche 2, (ii) the Company having unrestricted cash and cash equivalents held in a deposit or securities account subject to a control agreement in favor of the Agent in a minimum amount of $20.0 million and (iii) there being no default under the MidCap Credit Facility. The MidCap Revolving Loan provides a secured revolving credit facility in an aggregate principal amount of up to $2.0 million. The Company may request an increase in the total commitments under the MidCap Revolving Loan by up to an additional $8.0 million, subject to agent and lender approval and the satisfaction of certain conditions. Availability of the revolving credit facility under the MidCap Revolving Loan will be based upon a borrowing base formula and periodic borrowing base certifications valuing certain of the Company’s accounts receivable and inventory, as reduced by certain reserves, if any. Further, although the revolving credit facility was made available following establishment of required lockbox arrangements by the Company in June 2018, there were no amounts outstanding under the MidCap Revolving Loan as of December 31, 2018. The proceeds of any loans under the MidCap Revolving Loan may be used for working capital and general corporate purposes. Loans under the MidCap Revolving Loan accrue interest at a floating rate equal to 4.25% per annum, plus the greater of (i) 1.25% or (ii) the one-month LIBOR. Accrued interest on the revolving loans will be paid monthly and revolving loans may be borrowed, repaid and re-borrowed until March 1, 2023, when all outstanding amounts must be repaid. Subject to certain exceptions, termination or permanent reductions of the revolving loan commitment under the MidCap Revolving Loan will be subject to termination fees in an amount equal to 3.0% of the commitment amount terminated or reduced if such termination or reduction occurs on or prior to the first anniversary of the MidCap Closing Date, 2.0% of the commitment amount terminated or reduced if such termination or reduction occurs after the first anniversary of the MidCap Closing Date but on or prior to the second anniversary of the MidCap Closing Date, and 1.0% of the commitment amount terminated or reduced if such termination or reduction occurs after the second anniversary of the MidCap Closing Date and prior to or on the third anniversary of the MidCap Closing Date. In connection with the MidCap Revolving Loan, the Company is required to pay customary fees, including an origination fee of 0.50% of the original commitment amount at closing (and an equivalent origination fee with respect to any increased commitments at the time of the applicable increase), a monthly unused line fee of 0.50% per annum based upon the average daily unused portion of the revolving credit facility and a monthly collateral management fee of 0.50% per annum based upon the average daily used portion of the revolving credit facility. The Company is also required to maintain a minimum drawn balance of not less 20% of availability under the revolving line. If the Company does not maintain such minimum drawn balance, it is required to pay monthly interest and fees as if an amount equal to 20% of availability had been drawn down under the revolving line. The Company’s obligations under the MidCap Credit Facility are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company’s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Facility. The MidCap Credit Facility contains customary affirmative covenants and customary negative covenants limiting the Company’s ability and the ability of the Company’s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions. Commencing with the calendar quarter ending on the later of (a) June 30, 2019 and (b) the last day of the calendar quarter in which MidCap Tranche 2 is funded, the Company must also comply with a financial covenant relating to trailing twelve-month minimum Net Revenue requirements (as defined in the MidCap Credit Facility), tested on a quarterly basis. The MidCap Credit Facility also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company’s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, agent and the lenders may declare all or a portion of the Company’s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by 3.0%. The Company granted the lender ten-year warrants to purchase 18,123 shares of the Company’s common stock at $7.73 per share as a result of Tranche 1. Upon drawdown of Tranche 2, the Company will issue additional ten-year warrants to purchase shares of the Company’s common stock in an aggregate amount equal to 2.0% of the amount drawn, divided by the exercise price per share for that tranche (defined as 1.5 times the volume-weighted average closing price of the Company’s common stock for the ten business days immediately preceding the business day before the issue date). The fair value of the warrants on the date of issuance was approximately $74,000, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the MidCap Term Loan. The Company has recognized approximately $610,359 of unamortized debt discount associated with the MidCap Term Loan, resulting from fees and debt issuance costs, in the accompanying consolidated balance sheets as of December 31, 2018. Amortization of the debt discount associated with the MidCap Term Loan was approximately $121,611 for the year ended December 31, 2018 and was included in interest expense in the accompanying consolidated statements of operations. Unamortized costs incurred in connection with the issuance of the Midcap Revolving Loan of $67,068 as of December 31, 2018 are presented as deferred MidCap revolving loan costs in the accompanying consolidated balance sheets. Amortization of deferred MidCap revolving loan costs was $12,352 for the year ended December 31, 2018, and is included in interest expense in the accompanying consolidated statements of operations. There were no costs associated with the MidCap Term Loan or the MidCap Revolving Loan for the year ended December 31, 2017. Other Debt Obligations to Related Parties Refer to Note 16 below for discussion of debt obligations to related parties.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	Dec. 31, 2018
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	Note 9. Revenue from Contracts with Customers Revenue from contracts with customers is recognized when, or as, the Company satisfies its performance obligations by delivering the promised goods or service deliverables to the customers. A good or service deliverable is transferred to a customer when, or as, the customer obtains control of that good or service deliverable. A performance obligation may be satisfied over time or at a point in time. Revenue from a performance obligation satisfied over time is recognized by measuring the Company’s progress in satisfying the performance obligation in a manner that depicts the transfer of the goods or services to the customer. Revenue from a performance obligation satisfied at a point in time is recognized at the point in time that the Company determines the customer obtains control over the promised good or service deliverable. The amount of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for those promised goods or services ( i.e. Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the years ended December 31, 2018 and 2017 as follows: Years Ended December 31, 2018 2017 Product revenue: Instrument $ 351,885 $ 385,143 Consumables 1,964,499 1,463,347 Total product revenue 2,316,384 1,848,490 Product-related services revenue: Custom RUO assay design 964,241 419,515 Sample processing 5,840,765 4,529,250 Total product-related services revenue 6,805,006 4,948,765 Total product and product-related services revenue $ 9,121,390 $ 6,797,255 Because the Company’s agreements for product and product-related services revenue have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations. Sale of instruments and consumables The delivery of each instrument and related installation and calibration are considered to be a single performance obligation, as the HTG EdgeSeq instrument must be professionally installed and calibrated prior to use. Instrument product revenue is generally recognized upon installation and calibration of the instrument by field service engineers, which represents the point at which the customer has the ability to use the instrument and has accepted the asset. Installation generally occurs within one month of instrument shipment. The delivery of each consumable is a separate performance obligation. Consumables revenue is recognized upon transfer of control, which represents the point when the customer has legal title and the significant risks of ownership of the asset. The Company’s standard terms and conditions provide that no right of return exists for instruments and consumables, unless replacement is necessary due to delivery of defective or damaged product. Customer payment terms vary but are typically between 30 and 90 days of revenue being earned from shipment or delivery, as applicable. Shipping and handling fees charged to the Company’s customers for instruments and consumables shipped are included in the accompanying consolidated statements of operations as part of product and product-related services revenue. Shipping and handling costs for sold products shipped to the Company’s customers are included in the accompanying consolidated statements of operations as part of cost of product and product-related services For sales of consumables in the United States, standard delivery terms are FOB shipping point, unless otherwise specified in the customer contract, reflecting transfer of control to the customer upon shipment. The Company has elected the practical expedient to account for shipping and handling as activities to fulfill the promise to transfer the consumables. The Company provides instruments to certain customers under reagent rental agreements. Under these agreements, the Company installs instruments in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances, the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. The Company measures progress toward complete satisfaction of its performance obligation to provide the instrument and deliver the consumables using an output method based on the number of consumables delivered in relation to the total consumables to be provided under the reagent rental agreement. This is considered to be representative of the delivery of outputs under the arrangement and the best measure of progress because the customer benefits from the instrument only in conjunction with the consumables. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. The cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase, in which case the instrument would be expensed as cost of product and product-related services Service Revenue Sample Processing The Company also provides sample preparation and processing services and molecular profiling of retrospective cohorts for its customers through its VERI/O laboratory, whereby the customer provides samples to be processed using HTG EdgeSeq technology specified in the order. Customers are charged a per sample fee for sample processing services which is recognized as revenue upon delivery of a data file to the customer showing the results of testing and completing delivery of the agreed upon service. This is when the customer can use and benefit from the results of testing and the Company has the present right to payment. Custom RUO Assay Design and Related Agreements The Company enters into custom RUO assay design agreements that may generate up-front fees and subsequent payments that might be earned upon completion of design process phases. The Company measures progress toward complete satisfaction of its performance obligation to perform custom RUO assay design using an output method based on the costs incurred to date compared to total expected costs, as this is representative of the delivery of outputs under the arrangements and the best measure of progress. However, because in most instances the assay development fees are contingent upon completion of each phase of the design project and the decision of the customer to proceed to the next phase, the amount to be included in the transaction price and recognized as revenue is limited to that which the customer is contractually obligated to pay upon completion of that phase, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Collaborative Development Services Revenue Years Ended December 31, 2018 2017 Collaborative development services $ 12,382,504 $ 7,962,312 See Note 16 for discussion of collaborative development services contracts with related parties. There was $0 and $25,000 of Contract Liabilities The Company receives up-front payments from customers for custom RUO assay design services, and occasionally for sample processing services. Payments for instrument extended warranty contracts are made in advance as are payments for certain agreed-upon capital purchases required for collaborative development service projects. The Company recognizes such up-front payments as a contract liability. The contract liability is subsequently reduced at the point in time that the data file is delivered for sample processing services or as the Company satisfies its performance obligations over time for RUO assay design, collaborative development and extended warranty services. Contract liabilities of $410,947 and $837,885 were included in contract liabilities – current and other non-current liabilities in the accompanying consolidated balance sheets as of December 31, 2018 and 2017, respectively. Changes in the Company’s contract liability were as follows as of the date indicated: Product Revenue Custom RUO Assay Design Sample Processing Collaborative Development Services Total Contract Liability Balance at January 1, 2018 $ 39,426 $ 197,606 $ 490,536 $ 110,317 $ 837,885 Deferral of revenue 190,703 448,580 197,541 70,918 907,742 Customer deposits 131,864 — — — 131,864 Recognition of deferred Revenue (245,446 ) (596,186 ) (443,677 ) (181,235 ) (1,466,544 ) Balance at December 31, 2018 $ 116,547 $ 50,000 $ 244,400 $ — $ 410,947

Other Agreements

Other Agreements	12 Months Ended
	Dec. 31, 2018
Other Agreements [Abstract]
Other Agreements	Note 10. Other Agreements NuvoGen Obligation The Company entered into an asset purchase agreement in 2001, as amended, with NuvoGen Research, LLC (“NuvoGen”) to acquire certain intellectual property from NuvoGen. The Company accounted for the transaction as an asset acquisition. However, as the intellectual property was determined to not have an alternative future use, the upfront consideration was expensed. In exchange for the intellectual property, the Company initially paid NuvoGen 5,587 shares of the Company’s common stock, fixed payments of $740,000 over the first two years of the agreement and agreed to pay NuvoGen the greater of $400,000 annually, in quarterly installments, or 6% of its yearly revenue, which percentage payment would be reduced by any fixed payment installments made during the applicable period, until the total aggregate cash compensation paid to NuvoGen under the agreement equaled $15,000,000. Certain terms of the agreement were amended in November 2003, September 2004, November 2012 and February 2014. Pursuant to the latest amendment to the agreement, the Company paid yearly fixed fees, in quarterly installments, to NuvoGen of $400,000 and $800,000 for the years ended December 31, 2018 and 2017, respectively. Although the amendment allowed for the deferral of any revenue-based payments through December 31, 2017, no revenue-based payments have been deferred, and additional revenue-based payments of $363,686 and $85,574 were payable as of December 31, 2018 and 2017, respectively, for the amount by which 6% of revenue exceeded the applicable fixed fee. As of January 1, 2019, the Company, again, is obligated to pay the greater of $400,000 or 6% of annual revenues until the obligation is paid in full. As of that date and continuing until the remaining obligation has been paid in full, interest on the remaining unpaid obligation will accrue and compound annually at a rate of 2.5% per year. Accrued interest on this unpaid obligation is payable on the date that the remaining obligation is paid in full. The obligation was, but is no longer, secured by certain patents and trademarks. Minimum payments to be made in 2019 include $363,686 of revenue-based payments payable as of December 31, 2018 and an estimate of additional revenue-based payments to be made throughout the remainder of 2019 relating to revenue generated in the first, second and third quarters of 2019 using actual revenue generated in the same quarters in 2018. Minimum payments for the remaining years include only the minimum payments for each year. Actual payments could be significantly more than provided in the table, to the extent that 6% of the Company’s annual revenue in 2020 and beyond exceeds $400,000: 2019 $ 1,290,234 2020 400,000 2021 400,000 2022 400,000 2023 400,000 2024 and beyond 3,996,387 Total NuvoGen obligation payments 6,886,621 Plus interest accretion 106,132 Total NuvoGen obligation, net $ 6,992,753 The Company has recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, the Company’s estimate of its effective borrowing rate for similar obligations. The unamortized debt discount was $(106,132) and $(118,612) at December 31, 2018 and 2017, respectively. Discount accreted during the years ended December 31, 2018 and 2017 was $(12,480), and $195,248, respectively. Illumina, Inc. Agreement In June 2017, the Company entered into an Amended and Restated Development and Component Supply Agreement with Illumina, Inc., (“Illumina”), effective May 31, 2017 (the “Restated Agreement”), which amended and restated the parties’ IVD Test Development and Component Supply Agreement entered into in October 2014 (the “Original Agreement”). The Restated Agreement provides for the development and worldwide commercialization by the Company of nuclease-protection-based RNA or DNA profiling tests (“IVD test kits”) for use with Illumina’s MiSeqDx sequencer in the field of diagnostic oncology testing in humans (the “Field”). Under the Restated Agreement, the parties have agreed to continue activities under the first development plan which was entered into pursuant to the Original Agreement, and the Company may, at its discretion, submit additional development plans for IVD test kits in the Field to Illumina for its approval, not to be unreasonably withheld. Under each development plan, Illumina will provide specified regulatory support and rights, and develop and deliver to the Company an executable version of custom software, which, when deployed on Illumina’s MiSeqDx sequencer, would enable sequencing by the end-user of the subject IVD test kit probe library. Illumina retains ownership of the custom software, subject to the Company’s right to use the custom software in connection with the commercialization of IVD test kits. The Company is required to pay Illumina up to $0.6 million in the aggregate upon achievement of specified regulatory milestones relating to the IVD test kits, though none of these regulatory milestones have been reached through December 31, 2018. In addition, the Company has agreed to pay Illumina a single digit percentage royalty on net sales of any IVD test kits that the Company commercializes pursuant to the Restated Agreement. As a result of IVD test kit development plans submitted by the Company to Illumina in accordance with the Restated Agreement, the Company paid Illumina $12,500 and $50,000 for the years ended December 31, 2018 and 2017, respectively. Costs incurred for development plans under the Restated Agreement have been expensed as incurred to research and development expense in the accompanying consolidated statements of operations. Absent earlier termination, the Restated Agreement will expire in May 2027; however, Illumina is no longer obligated to notify the Company of changes in its products that may affect the Company’s IVD test kits after May 31, 2023. The Company may terminate the Restated Agreement at any time upon 90 days’ written notice and may terminate any development plan under the Restated Agreement upon 30 days’ prior written notice. Illumina may terminate the Restated Agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control, subject to a transition period of up to 12 months for then-ongoing development plans. Either party may terminate the Restated Agreement upon the other party’s material breach of the Restated Agreement that remains uncured for 30 days, or upon the other party’s bankruptcy. Other Agreements with Related Parties Refer to Note 16 below for discussion of agreements with related partie s.

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Net Loss per Share	Note 11. Net Loss Per Share Basic loss per common share is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Years Ended December 31, 2018 2017 Numerator: Net loss $ (16,453,918 ) $ (18,960,017 ) Denominator: Weighted-average shares outstanding-basic and diluted 27,523,463 10,597,318 Net loss per share, basic and diluted $ (0.60 ) $ (1.79 ) The following outstanding options, warrants, restricted stock units and debt conversion option were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Years Ended December 31, 2018 2017 Options to purchase common stock 2,047,237 1,517,771 Common stock warrants 237,846 219,723 Restricted stock units 227,707 26,666 QNAH convertible note 777,769 755,178

Warrants

Warrants	12 Months Ended
	Dec. 31, 2018
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Warrants	Note 12. Warrants In connection with certain of its redeemable convertible preferred stock issuances, convertible debt financings and other financing arrangements, the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock which have since been converted to common stock warrants. On August 22, 2014, in connection with the Company’s entry into the Growth Term Loan (see Note 8), the Company issued to the two-lender syndicate warrants exercisable for an aggregate of 2,512,562 shares of Series E stock at a price of $0.2189 per share. The warrants provide for cashless exercise at the option of the holders, and contain provisions for the adjustment of the number of shares issuable upon the exercise of the warrant in the event of stock splits, recapitalizations, reclassifications, consolidations or dilutive issuances. In connection with the closing of the IPO in May 2015, the warrants became exercisable for an aggregate of 23,396 shares of common stock at an exercise price of $23.51 per share. The warrants expire by their terms on August 22, 2024, provided that the warrants will be automatically exercised on a cashless basis upon expiration if not previously exercised if the fair market value of a share of the common stock exceeds the per share exercise price. In connection with the funding of Growth Term Loan B, in March 2016 the Company issued Oxford Finance LLC a common stock warrant exercisable for 45,307 shares of common stock at an exercise price of $2.759 per share, and the warrant originally issued to Silicon Valley Bank automatically became exercisable for an additional 5,317 shares of common stock at an exercise price of $23.51 per share in accordance with the terms of the Growth Term Loan. On December 30, 2014, in connection with the Company’s entry into convertible note agreements, the Company agreed to issue warrants (“Convertible Note Warrants”) to the holders exercisable for an aggregate of 9,311,586 shares of Series E Stock at a price of $0.2189 per share, for aggregate consideration of $1,354 on January 15, 2015. The warrants provide for cashless exercise at the option of the holders, and contain provisions for the adjustment of the number of shares issuable upon the exercise of the warrant in the event of stock splits, recapitalizations, reclassifications, consolidations or dilutive issuances. In connection with the closing of the IPO in May 2015, the Convertible Note Warrants became exercisable for an aggregate of 144,772 shares of common stock at the IPO price of $14.00 per share. The Convertible Note Warrants expire by their terms on January 15, 2022. The following table shows the common stock warrants outstanding as of December 31, 2018: Shares of Common Underlying Warrants Exercise Price/Share Expiration Date 28,713 $ 23.51 2024 144,772 14.00 2022 931 6.45 2019 45,307 2.76 2026 18,123 7.73 2028

Stockholders Deficit

Stockholders Deficit	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Stockholders' Deficit	Note 13. Stockholders’ Deficit Public Offerings ATM Offering In April 2017, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), as sales agent, pursuant to which the Company had the right to offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.001 per share, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “ATM Offering”). In April 2017, the Company also filed a prospectus supplement (File No. 333-216977) with the SEC relating to the offer and sale of up to $20.0 million of common stock in the ATM Offering. In June 2017, the Company filed a first amendment to the prospectus supplement with the SEC to increase the amount of common stock that could be offered and sold in the ATM Offering under the Sales Agreement to $40.0 million in the aggregate, inclusive of the common stock previously sold in the ATM Offering prior to the date of the first amendment. In January 2018, the Company filed a second amendment to the prospectus supplement with the SEC to decrease the amount of common stock that could be offered and sold in the ATM Offering under the Sales Agreement to $23.0 million in the aggregate, inclusive of the common stock sold in the ATM Offering prior to the date of the second amendment. In February 2018, the Company and Cantor mutually agreed to terminate the Sales Agreement. Prior to termination of the Sales Agreement, the Company sold 5,733,314 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of approximately $21.1 million, including 0.3 million shares of common stock sold for gross proceeds of $0.6 million during the first quarter ended March 31, 2018. After $0.6 million of sales commissions and $0.2 million of other offering expenses paid by the Company in connection with the ATM Offering, the Company’s aggregate net proceeds from the ATM Offering were approximately $20.2 million. Sales commissions and offering expenses have been recorded as a reduction of proceeds received in arriving at the amounts recorded in additional paid-in capital in the accompanying consolidated balance sheets as of December 31, 2018 and 2017. Underwritten Public Offering In January 2018, the Company completed an underwritten public offering of 13,915,000 shares of its common stock at a price of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The Company sold its common stock through an underwriting agreement with Leerink Partners LLC and Cantor as representatives of the underwriters for the offering. The aggregate net proceeds to the Company from the offering were approximately $37.7 million, after deducting the underwriting discounts and commissions and offering expenses. Common Stock Pursuant to the Company Amended and Restated Certificate of Incorporation, the Company is authorized to issue 200,000,000 shares of common stock at a par value of $0.001 per share. As of December 31, 2018, 28,585,449 shares were issued and outstanding. As of December 31, 2017, 13,929,763 shares were issued and outstanding. Each share of common stock is entitled to one vote. The shares of common stock have no preemptive or conversion rights, no redemption or sinking fund provisions, no liability for further call or assessment, and are not entitled to cumulative voting rights. Treasury Stock Shares of common stock repurchased by the Company are recorded as treasury stock and result in an increase of stockholders’ deficit on the consolidated balance sheets. Reacquired common shares may be retired by resolution of the Board of Directors and resume the status of authorized and unissued common shares. In January 2017, the Company’s Board of Directors retired 1,396 shares of treasury stock to be returned to the status of authorized and unissued shares of the Company’s common stock. There was no additional treasury stock activity for the years ended December 31, 2018 and 2017. Preferred Stock Pursuant to the Company’s certificate of incorporation the Company has been authorized to issue 10,000,000 shares of preferred stock, each having a par value of $0.001. The preferred stock may be issued from time to time in one or more series with the authorization of the Company’s Board of Directors. The Board of Directors can determine voting power for each series issued, as well as designation, preferences, and relative, participating, optional or other rights and such qualifications, limitations or restrictions thereof. Stock-based Compensation The Company incurs stock-based compensation expense relating to the grants under its equity incentive plans of RSUs and stock options to employees, non-employee directors and consultants of the Company and its affiliates and through its employee stock purchase plan. Amounts recognized in the accompanying consolidated statements of operations with respect to the Company’s stock-based compensation and employee stock purchase plan were as follows: Years Ended December 31, 2018 2017 Selling, general and administrative $ 1,709,945 $ 1,012,253 Research and development 172,005 319,916 Cost of product and product-related services revenue 65,064 103,918 $ 1,947,014 $ 1,436,087 Equity Incentive Plans The Company initially established the 2001 Stock Option Plan (the “2001 Plan”), which included incentive and nonqualified stock options and restricted stock to be granted to directors, officers, employees, consultants and others. The 2001 Plan terminated, and no further awards were granted under the 2001 Plan upon the effective date of the Company’s 2011 Equity Incentive Plan (the “2011 Plan”). In February 2014, the number of shares reserved under the 2011 Plan was increased to 20% of the total outstanding shares of the Company calculated on a fully diluted basis. The shares reserved under the 2011 Plan were required to be kept at that percentage with each subsequent equity financing. No new equity awards may be granted under the 2011 Plan. On May 11, 2015, 940,112 shares were reserved for issuance under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), including 14,006 remaining shares reserved under the 2011 Plan. As of December 31, 2018, there were no shares available for issuance under the 2014 Plan. On January 1, 2019, an additional 1,143,417 shares were registered for issuance under the 2014 Plan pursuant to an evergreen provision contained in the 2014 Plan. The Company’s Board of Directors determines the grant date for all awards granted under the 2014 Plan. The option exercise price of stock options granted is generally equal to the closing price of the Company’s common stock on the date of grant. All stock options granted have a ten-year term. The vesting period of stock options and RSUs is established by the Board of Directors but typically ranges between one and four years. The following table summarizes stock option activity during the two-year period ended December 31, 2018: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at January 1, 2017 1,161,705 $ 3.35 7.7 $ 36,887 Granted 494,500 2.09 Exercised (41,815 ) 2.68 $ 152,130 Forfeited (81,676 ) 2.64 Expired/Cancelled (14,943 ) 6.15 Balance at December 31, 2017 1,517,771 $ 2.97 7.5 $ 67,242 Granted 802,500 3.39 Exercised (144,645 ) 2.19 $ 243,531 Forfeited (66,428 ) 3.24 Expired/Cancelled (61,961 ) 6.52 Balance at December 31, 2018 2,047,237 $ 3.07 7.6 $ 366,007 Vested and expected to vest at December 31, 2018 2,047,237 $ 3.07 7.6 $ 366,007 Exercisable at December 31, 2017 851,996 $ 3.31 6.5 $ 248 Exercisable at December 31, 2018 1,256,352 $ 2.91 6.5 $ 346,595 The weighted-average fair value of stock options granted was $2.29 and $1.14 for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, total unrecognized compensation cost related to stock option awards was approximately $1,675,285, which is expected to be recognized over approximately 3.04 years. In June 2018, in connection with the retirement of two employees, the vesting of stock options covering 46,613 shares of common stock was accelerated and the post-termination exercise period for the employees’ options was extended to a one-year period from the termination date. As a result of this modification, the Company recorded incremental stock-based compensation expense of approximately $79,400 for the year ended December 31, 2018. The fair value of each stock option granted has been determined using the Black-Scholes option pricing model. The material factors incorporated in the Black-Scholes model in estimating the fair value of the stock options granted for the periods presented were as follows: 2018 2017 Fair value of common stock $3.26 - 5.06 $1.71 - 3.46 Risk-free interest rate 2.59% - 2.82% 1.75% - 2.20% Expected volatility 79.5% - 85.8% 58.5% - 62.6% Expected term 5.3 to 5.5 years 5.1 to 6.3 years Expected dividend yield 0% 0% • Expected stock price volatility • Risk-free interest rate • Expected term • Expected dividend yield In preparing its Black-Scholes option-pricing model fair value calculations, in accordance with ASU No. 2016-09, the Company does not estimate a forfeiture rate to calculate stock-based compensation. The Company uses judgment in evaluating the expected volatility and expected terms utilized for the Company’s stock-based compensation calculations on a prospective basis. The following table summarizes RSU award activity during the two-year period ended December 31, 2018: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at January 1, 2017 355,499 $ 2.41 Granted 10,000 1.75 Vested (336,333 ) 2.47 Forfeited (2,500 ) 2.46 Balance at December 31, 2017 26,666 $ 2.78 Granted 492,051 3.63 Released (291,010 ) 3.72 Balance at December 31, 2018 227,707 $ 3.30 Vested and unissued at December 31, 2018 13,126 $ 3.40 The weighted-average fair value of RSUs granted was $3.63 and $1.75 for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, total unrecognized compensation cost related to RSU awards was approximately $701,780, which is expected to be recognized over approximately 3.30 years. Vested and unissued awards at December 31, 2018 represents RSU awards granted on August 16, 2018 for which the second vesting date was December 31, 2018, but for which issuance of awards occurred on the next business day, January 2, 2019. 2014 Employee Stock Purchase Plan In April 2015, the Company’s stockholders approved the 2014 Employee Stock Purchase Plan (“ESPP”), which became effective in May 2015. Initially, the ESPP authorized the issuance of up to 110,820 shares of common stock pursuant to purchase rights granted to the Company’s employees or to employees of any of the Company’s designated affiliates. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year, from January 1, 2016 to January 1, 2024 by the least of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 195,000 shares, or (iii) a number determined by the Company’s board of directors that is less than (i) and (ii). The ESPP enables participants to contribute up to 15% of such participant’s eligible compensation during a defined period (not to exceed 27 months) to purchase common stock of the Company. The purchase price of common stock under the ESPP is the lesser of: (i) 85% of the fair market value of a share of the Company’s common stock on the first day of an offering or (ii) 85% of the fair market value of the Company’s common stock at the applicable purchase date. During the year ended December 31, 2018, employees purchased 39,993 shares at $1.57 per share, 35,805 shares at $1.57, and 4,176 shares at $2.81 per share at the end of each of the ESPP’s six-month purchase periods. During the year ended December 31, 2017, employees purchased 39,972 shares at $1.79 per share and 39,969 shares at $1.61 per share at the end of each of the ESPP’s six-month purchase periods. As of December 31, 2018, approximately 158,067 shares of the Company’s common stock were reserved for future issuance under the ESPP. On January 1, 2019, an additional 195,000 shares were registered for issuance pursuant to an evergreen provision contained in the ESPP. The Company recognizes ESPP expense based on the fair value of the ESPP stock purchase rights, estimated for each six-month purchase period using the Black-Scholes option pricing model. The model requires the Company to make subjective assumptions, including expected stock price volatility, risk free rate of return and estimated life. The fair value of equity-based awards is amortized straight-line over the vesting period of the award. The material factors incorporated in the Black-Scholes model in estimating the fair value of the ESPP awards for the periods presented were as follows: 2018 2017 Fair value of common stock $1.85 - 4.00 $2.11 - 3.17 Risk-free interest rate 1.88% - 2.07% 0.61% - 1.12% Expected volatility 83.2% - 85.8% 68.0% - 70.0% Expected term 0.5 years 0.5 years Expected dividend yield 0% 0% • Fair value of common stock • Expected stock price volatility • Risk-free interest rate • Expected term • Expected dividend yield Stock Purchase Plan In December 2015, the Board of Directors adopted a Stock Purchase Plan (the “Purchase Plan”) which allows directors, any individual deemed by the Board of Directors to be an officer for purposes of Section 16 of the Exchange Act, and anyone designated by the Board of Directors as eligible to participate in the Purchase Plan to purchase shares of the Company’s common stock from the Company at fair market value. The aggregate number of shares of common stock that may be issued under the Purchase Plan shall not exceed 250,000 shares of common stock, and a maximum of 7,500 shares of common stock may be purchased by any one participant on any one purchase date. The Board of Directors or an authorized committee must review and approve each individual request to purchase common stock under the Purchase Plan. Cash received from the sale of common stock by the Company to eligible participants for the year ended December 31, 2018 was $9,997 which resulted in the sale of 2,304 shares of the Company’s common stock at fair market value. Cash received from the sale of common stock by the Company to eligible participants for the year ended December 31, 2017 was $130,649 which resulted in the sale of 61,141 shares of the Company’s common stock at fair market value.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14. Commitments and Contingencies Compensation Agreements In September 2017, the Company entered into an arrangement with certain of its non-executive officer employees to provide for retention bonus payments to those eligible employees providing continuing service to the Company through July 31, 2018 and December 31, 2018, with one half of the retention bonus commitment payable at each of these dates. For the years ended December 31, 2018 and 2017, compensation expense of $881,336 and $358,744 has been included in the accompanying consolidated statements of operations. No forfeiture rate was estimated for this accrued liability. Instead, forfeitures were recognized as they occurred during the period. $635,377 and $358,744 of accrued retention bonus was included in accrued liabilities in the accompanying consolidated balance sheets as of December 31, 2018 and 2017, respectively. The remaining payment was made to eligible employees in January 2019. Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Employment Agreements The Company has entered into employment agreements or other arrangements with certain named executive officers, which provides salary continuation payments, bonuses and, in certain instances, the acceleration of the vesting of certain equity awards to individuals in the event that the individual is terminated other than for cause, as defined in the applicable agreement. Indemnification Agreements In the course of operating its business, the Company has entered into, and continues to enter into, separate indemnification agreements with the Company’s directors and executive officers, in addition to the indemnification provided for in the Company’s amended and restated bylaws. These agreements may require the Company to indemnify its directors and executive officers for certain expenses incurred in any action or proceeding arising out of their services as one of the Company’s directors or executive officers. Leases The Company leases office and laboratory space under two non-cancelable operating leases in Tucson, Arizona. The Company amended its facilities leases in August 2015 to extend the terms for approximately five years and to receive lessor approval for and establish lessee oversight of leasehold improvements by the Company and the lessor, respectively, which improvements expanded and improved the Company’s existing research, development, operations and administrative office facilities. The lease amendments included an increase of $804,000 in total monthly rent over the remaining term of the leases. The landlord constructed certain of the leasehold improvements as an incentive to extend the leases. The total cost of the improvements constructed by the landlord of $710,000 was capitalized when the construction was completed in February 2016, and is being depreciated over the remaining term of the lease agreement. The incentive of $710,000 has been recognized as deferred rent within other current liabilities and other liabilities on the consolidated balance sheets, and is being accreted at $11,833 per month over the lease term as a reduction of rent expense. In December 2018, HTG France signed a commercial lease for office and laboratory space in Sausheim, France effective January 1, 2019. The term of the lease is nine years, extending through December 31, 2028. However, HTG France maintains the right under this agreement to terminate the lease once every three years, subject to a prior notice period to the landlord of six months. Annual fixed lease payments under this agreement are 8,200 Euro plus service charges of 1,200 Euro, to be paid to the landlord on a monthly basis. The Company’s annual minimum lease payments relating to its Tucson and Sausheim facilities leases before common area maintenance charges are as follows as of December 31, 2018: 2019 $ 525,745 2020 528,225 2021 53,907 2022 10,768 2023 10,768 2024 and beyond 43,073 $ 1,172,486 Rent expense, including common area maintenance costs for the Company’s facilities leases was $583,182, including $142,000 of depreciation for capitalized leasehold improvements for the year ended December 31, 2018. Rent expense, including common area maintenance costs for the Company’s facility leases was $570,979, including $142,000 of depreciation for capitalized leasehold improvements for the year ended December 31, 2017. As of December 31, 2018, the Company also has capital lease commitments consisting of approximately $92,445 under leases for computer equipment varying in length from 36-48 months that have not been included in the minimum lease payments schedule above. Product Warranty The following is a summary of the Company’s general product warranty liability, which is included in accrued liabilities in the accompanying consolidated balance sheets for the years ended December 31, 2018 and 2017: Years Ended December 31. 2018 2017 Beginning balance $ 37,156 $ 50,426 Cost of warranty claims (2,596 ) (9,814 ) Increase in warranty reserve 28,901 (3,456 ) Ending balance $ 63,461 $ 37,156 Defined Contribution Plan In January 2003, the Company established a defined contribution plan (“401(k) Plan”) under section 401(k) of the IRC. All employees who are over the age of 21 and who are expected to work at least 1,000 hours in a calendar year are eligible for participation in the 401(k) Plan upon commencement of employment with the Company. The Company may make discretionary contributions to the 401(k) Plan, but has not done so during the years ended December 31, 2018 and 2017.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 15. Income Taxes The Company provides for income taxes based upon management’s estimate of taxable income or loss for each respective period. The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. These temporary differences would result in deductible or taxable amounts in future years, when the reported amounts of the assets are recovered or liabilities are settled, respectively. In each period since inception, the Company has recorded a valuation allowance for the full amount of its net deferred tax assets, as the realization of the net deferred tax assets is uncertain. As a result, the Company has not recorded any federal or state income tax benefit in the accompanying consolidated statements of operations; however, state income tax expense has been recorded for state minimum taxes. The Company periodically reviews its filing positions for all open tax years in all U.S. federal, state and international jurisdictions where the Company is or might be required to file tax returns or other required reports. The Company applies a two-step approach to recognizing and measuring uncertain tax positions. The Company evaluates the tax position for recognition by determining if the weight of available evidence indicates that it is “more likely than not” that the position will be sustained on audit, including resolution of related appeals or litigation process, if any. The term “more likely than not” means a likelihood of more than 50 percent. If the tax position is not more likely than not to be sustained in a court of last resort, the Company may not recognize any of the potential tax benefit associated with the position. The Company recognizes a benefit for a tax position that meets the more likely than not criterion at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon its effective resolution. Unrecognized tax benefits involve management’s judgment regarding the likelihood of the benefit being sustained. The final resolution of uncertain tax positions could result in adjustments to recorded amounts and may affect the Company’s results of operations, financial position and cash flows. As discussed below, the Company has estimated $1,538,220 and $0 of uncertain tax positions as of December 31, 2018 and 2017, respectively. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties at December 31, 2018 or 2017, and has not recognized interest or penalties during the years ended December 31, 2018 and 2017, since there was no reduction in income taxes paid due to uncertain tax positions. Management of the Company does not expect a material change to the amount of unrecognized tax benefits to occur within the next 12 months. The components of income tax expense are as follows: Years Ended December 31, 2018 2017 Current: Federal $ — $ — State 3,526 2,921 Total current income tax expense $ 3,526 $ 2,921 Deferred: Federal $ — $ — State — — Total deferred income tax expense $ — $ — Total income tax expense $ 3,526 $ 2,921 The Company’s actual income tax expense for the years ended December 31, 2018 and 2017 differ from the expected amount computed by applying the statutory federal income tax rate to loss before income taxes as follows: Years Ended December 31, 2018 2017 Computed tax (benefit) at statutory rate (2018: 21%, 2017: 34%) $ (3,454,582 ) $ (6,445,413 ) State taxes, net of federal benefit (384,035 ) (532,952 ) Stock-based compensation 82,024 231,396 Foreign tax rate differential (3,158 ) — Return to provision (31,111 ) (15,375 ) Other 51,598 20,292 Research and development tax credit - state (511,845 ) (576,525 ) Research and development tax credit - federal (506,364 ) (440,058 ) Federal rate change on deferred items as of enactment date — 16,232,211 Uncertain tax position adjustment for prior periods 1,029,115 — Increase (decrease) in valuation allowance 3,731,884 (8,470,655 ) $ 3,526 $ 2,921 Deferred tax assets and liabilities comprise the following: Years Ended December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 33,431,082 $ 29,475,597 Research and development credits 3,076,441 3,114,091 Deferred revenue 86,567 204,061 Inventory reserve 9,645 15,134 Fixed assets and intangibles 223,767 147,395 Accrued NuvoGen liability 1,720,335 1,952,567 Accrued expense 86,034 24,500 Other 106,913 74,986 38,740,784 35,008,331 Valuation allowance (38,740,784 ) (35,008,331 ) Deferred tax asset, net $ — $ — On December 22, 2017, the U.S. government enacted the Tax Act, which makes broad and complex changes to the IRC. Certain of these changes are applicable to the Company in 2018 and thereafter, including but not limited to, reducing the U.S. federal corporate tax rate from 35% to 21%, creating a new limitation on deductible interest expense, eliminating the corporate alternative minimum tax, modifying the rules related to uses and limitations of net operating loss carryforwards generated in tax years ending after December 31, 2017, enhancing bonus depreciation, and changing the rules pertaining to the taxation of profits earned abroad. Changes in tax rates and tax laws are accounted for in the period of enactment. The Tax Act reduced the corporate tax rate to 21% effective January 1, 2018. Consequently, the Company recorded a decrease related to deferred tax assets of $16,232,211, exclusive of the corresponding change in the valuation allowance, as of December 31, 2017. Due to the full valuation allowance on the deferred tax assets, there was no net adjustment to deferred tax expense or benefit for the year ended December 31, 2017, resulting from the reduction of the corporate tax rate. As of December 31, 2018, the Company has estimated federal and state net operating loss (“NOL”) carryforwards of approximately $138,759,835 and $89,208,791 for federal and state income tax purposes, respectively. The Company’s federal NOLs are scheduled to expire from 2021 through 2038. The Company’s state NOLs are scheduled to expire from 2027 through 2038. The Company has an estimated French NOL carryforward of $38,618 as of December 31, 2018, with no expiration date. The Company’s federal and state tax credit carryforwards begin expiring in 2021 and 2019, respectively. Year of Expiration Carryforwards Federal NOL carryforwards 2021 $ 211,806 2023 1,635,651 2024 1,217,290 2025 1,409,498 2026 1,175,594 2027 1,676,458 2028 3,037,785 2029 3,753,314 2030 623,235 2031 5,435,312 2032 10,913,787 2033 12,095,966 2034 14,190,409 2035 21,112,183 2036 24,302,042 2037 18,986,265 2038 16,983,240 $ 138,759,835 For financial reporting purposes, valuation allowances of $38,740,784 and $35,008,331 at December 31, 2018 and 2017, respectively, have been established to offset deferred tax assets relating primarily to NOLs and research and development credits. The increase in the valuation allowance of $3,732,453 for the year ended December 31, 2018 was primarily due to increased operating losses. The Company has established a valuation allowance against its entire tax asset. As a result, the Company does not recognize any tax benefit until it is in a taxpaying position or there is sufficient positive evidence leading to the conclusion that it is more likely than not to realize the tax benefit. A reconciliation of the Company’s gross unrecognized tax benefits is as follows: Years Ended December 31, 2018 2017 Balance at beginning of year $ — $ — Increases to prior positions 1,029,115 Increases for current year positions 509,105 — Balance at end of year $ 1,538,220 $ — As of December 31, 2018, the Company had $1,538,220 of gross unrecognized tax benefits, related to research and experimental tax credits. The Company had no unrecognized tax benefits as of December 31, 2018, which, if recognized, would affect the annual effective tax rate, due to the full valuation allowance on the deferred tax assets. The Company files income tax returns in the United States, Arizona, California, Texas, various other state jurisdictions, and France ,

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 16. Related Party Transactions QML Master Assay Development, Commercialization and Manufacturing Agreement In November 2016, the Company and QML entered into the Governing Agreement, which creates a framework for QML and the Company to combine their technological and commercial strengths to offer biopharmaceutical companies a complete NGS-based solution for the development, manufacture and commercialization of companion diagnostic assays. Under the Governing Agreement, the parties jointly seek companion diagnostic programs with biopharmaceutical companies, QML enters into sponsor project agreements with interested biopharmaceutical companies for specified projects, and QML and the Company enter into statements of work, which set forth the rights and obligations of QML and the Company with respect to each project. The parties’ relationship under the Governing Agreement is exclusive in the oncology field. Such exclusivity in the oncology field may be lost and become non-exclusive if certain performance targets are not met. Projects may be undertaken in non-oncology fields at each party’s discretion on a non-exclusive basis. QML and the Company share net profits under each statement of work, based on whether development of particular assays under a statement of work are primarily based on HTG or QML intellectual property. Each statement of work provides additional financial terms for the corresponding Project, which terms depend on the respective development and/or commercialization activities of the parties. The Governing Agreement has a five-year term. However, either party may terminate the Governing Agreement upon (i) the other party’s uncured material breach, bankruptcy or insolvency, (ii) specified events affecting all statements of work, or (iii) a change of control by either party, except neither party will have such change of control termination right to the extent the termination of the Governing Agreement relates to SOW One, SOW Two or SOW Three (each defined below). In the event a party terminates the Governing Agreement for its own change of control, a $2.0 million termination payment will be payable to the non-terminating party. The Company has determined that SOW One, SOW Two and SOW Three (each defined below) are collaborative arrangements and that QML meets the definition of a customer under ASC 606. Additionally, each SOW is a separate contract with a single performance obligation to provide development services. Under each SOW, QML pays the Company a monthly fee for development work performed by the Company and its subcontractors. The monthly fee is based on the employee and materials costs incurred during the month, which is subject to significant variability from period to period and unknown until the costs are incurred. Therefore, the monthly fee, which is based on use of hours and costs as a measure of progress, is included in the transaction price and recognized as revenue over time when the costs are incurred and the monthly fee is billed to QML. As the Company has the right to consideration from the customer in an amount that corresponds directly to the value to the customer of its performance completed to date, revenue in the amount to which the Company has the right to invoice is recognized. It is at this time that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company and QML also will share any net profits resulting from performance of the development work as determined pursuant to the Governing Agreement. Such profit sharing payment(s) is deemed to be variable consideration using the expected value method and is included in the transaction price upon completion of the respective SOW deliverables, acceptance of corresponding deliverables, and the mutual agreement by QML and the Company on the calculation of net profit, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Because each SOW has an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations for each SOW Statement of Work No. One In June 2017, the Company and QML entered into the first statement of work under the Governing Agreement, which has been twice amended in December 2017 and March 2018 (collectively, “SOW One”). SOW One addressed the activities of the Company and QML in support of the development and potential commercialization of a next generation sequencing-based companion diagnostic assay that was the subject of a sponsor project agreement between QML and a biopharmaceutical company (“Pharma One”). In May 2018, SOW One was terminated by QML as a result of Pharma One’s termination of the development of its product candidate project. The Company discontinued development activities related to the project following wind down activities completed in the second quarter of 2018. Revenue of $2,297,742, including only SOW One Monthly Fees, and $99,394 of SOW One profit sharing payments has been included in collaborative development services revenue in the accompanying consolidated statements of operations for the year ended December 31, 2018, compared to $2,604,892 , including only SOW One Monthly Fees and $1,272,080 of SOW One profit sharing payments, for the year ended December 31, 2017. Costs relating to development activities conducted by the Company pursuant to SOW One of $1,716,115 and $2,129,138 have been included in research and development expense in the accompanying consolidated statements of operations for the years ended December 31, 2018 and 2017, respectively. Accounts receivable relating to SOW One of $0 and $2,429,152 remained in the accompanying consolidated balance sheets as of December 31, 2018 and 2017, respectively. Statement of Work No. Two In October 2017, the Company and QML entered into the second statement of work under the Governing Agreement (“SOW Two”), which was made effective as of June 2, 2017 (“Onset Date”). The Company and QML amended SOW Two twice in August 2018 and an additional time in September 2018. SOW Two addresses development activities conducted by the Company and QML since the Onset Date and those expected to be further conducted by parties in connection with what is expected to be a multi-stage project leading to the potential development and commercialization of an NGS-based companion diagnostic assay in support of one or more therapeutic product candidate development and commercialization programs for a third-party pharmaceutical company. The initial-phase investigational use only (“IUO”) development activities under SOW Two have been completed and the first two amendments of SOW Two relate to the next phases, which include the use of the IUO assay developed in the initial-phase in a retrospective clinical trial and in additional disease indications. The third amendment to SOW Two provides that profit sharing relating to the original development activities and the development activities contemplated by the first SOW Two amendment will, in each case, commence upon the later of (i) the third amendment effective date, which is September 27, 2018, and (ii) the completion of the respective development activities, rather than at the end of each calendar quarter, provided that such modification to the profit-sharing commencement date only applies to development activities that had not yet been subject to profit-sharing as of the third amendment effective date. QML will continue to pay the Company for the development services to be performed under SOW Two. The Company and QML will share in any net profits (as determined under the Governing Agreement) generated during the work on an approximately quarterly basis throughout the term of SOW Two, except as otherwise specified in the third amendment to SOW Two. The Supplement Agreement initially entered into concurrent with SOW Two was also amended in August 2018 and made effective as of July 2018. This amendment establishes certain rights and obligations of the parties with regard to confidential information and other intellectual property needed to perform, and/or produced as a result of the next phase project activities contemplated by the SOW Two amendments and does not materially change the terms and conditions agreed upon by the parties in the original Supplement Agreement. Revenue of $5,988,021, including SOW Two Monthly Fees of $4,208,194 and SOW Two profit sharing payments of $1,779,827, has been included in collaborative development services revenue in the accompanying consolidated statements of operations for the year ended December 31, 2018. Revenue of $4,060,341, including SOW Two Monthly Fees of $2,988,211 and SOW Two profit sharing payments of $1,072,130 has been included in collaborative development services revenue in the accompanying consolidated statements of operations for the year ended December 31, 2017. Costs relating to development activities conducted by the Company pursuant to SOW Two of $3,625,332 and $2,645,825 have been included in research and development expense in the accompanying consolidated statements of operations for the years ended December 31, 2018 and 2017, respectively. Accounts receivable relating to SOW Two of $1,007,950 and $1,796,157 remained in the accompanying consolidated balance sheets as of December 31, 2018 and 2017, respectively. Statement of Work No. Three In January 2018, the Company and QML entered into a third statement of work under the Governing Agreement (“SOW Three”) and amended SOW Three in September 2018. SOW Three relates to development activities for a next generation sequencing-based clinical-trial assay (“SOW Three Project”) in connection with a sponsor project agreement between QML and a pharmaceutical company (“Pharma Three”). Initial assay development activities under SOW Three have been completed, and the first amendment to SOW Three provides for the development of an IUO assay, subsequent retrospective testing of clinical trial samples, design verification and, subject to satisfactory achievement of relevant performance and regulatory milestones, regulatory submissions in the United States and EU necessary for the commercialization of a companion diagnostic for a corresponding Pharma Three drug. Under the terms of SOW Three, the Company has agreed to assign its rights in certain SOW Three Project-related intellectual property (“Project IP”) predominantly related to Pharma Three’s drug candidate(s) to QML for ultimate assignment to Pharma Three in accordance with the sponsor project agreement between QML and Pharma Three. Improvements to the background intellectual property of the Company, QML and Pharma Three generally will be owned solely by the respective party. Otherwise, Project IP will be jointly owned among the Company, QML and Pharma Three.The development activities to be performed under SOW Three are expected to extend through the first half of the fiscal year ended December 31, 2020, with key development milestones, testing and regulatory filings occurring throughout the period . QML will pay the Company for the development services performed for SOW Three. In addition, the Company and QML will share in any net profits (as determined under the Governing Agreement) generated during the work on an approximately quarterly basis throughout the term of SOW Three. Revenue of $3,997,346, including SOW Three Monthly Fees of $3,641,715 and SOW Three profit sharing payments of $355,631 have been included in collaborative development services revenue in the accompanying consolidated statements of operations for the year ended December 31, 2018. Costs relating to development activities conducted by the Company pursuant to SOW Three of $2,667,030 have been included in research and development expense in the accompanying consolidated statements of operations for the year ended December 31, 2018. No costs or revenue relating to SOW Three were included in the accompanying consolidated statements of operations for the year ended December 31, 2017 as SOW Three was not established until January 2018. Accounts receivable relating to SOW Three of $363,869 and $0 remained in the accompanying consolidated balance sheets as of December 31, 2018 and 2017, respectively. QNAH Stock Purchase Agreement Pursuant to a stock purchase agreement, entered concurrent with the Governing Agreement, QNAH, purchased 833,333 shares of the Company’s common stock on November 17, 2016 at $2.40 per share, for a total purchase price of $2.0 million. The purchase price for the shares of common stock purchased by QNAH reflected the parties’ agreement as to the fair market value of the shares. However, the portion of the purchase price per share that exceeded the most recently reported closing price of the Company’s common stock, or $175,000 in the aggregate, was attributed to the Governing Agreement and recorded as deferred revenue. This deferred revenue is being recognized on a straight-line basis over the Governing Agreement’s five-year term. The Company recognized $35,000 and $4,375 of this consideration as revenue for the years ended December 31, 2018 and 2017, respectively. The second tranche closing contemplated by the stock purchase agreement did not occur, and accordingly, QNAH did not purchase any additional shares under the stock purchase agreement. QNAH does not have, and as of December 31, 2017 did not have, any further obligation to purchase common stock under the stock purchase agreement. QNAH Convertible Note Agreement In October 2017, the Company issued a subordinated convertible promissory note to QNAH in the principal amount of $3.0 million against receipt of cash proceeds equal to such principal amount. The QNAH Convertible Note bears simple interest at the rate of 3.0% per annum and matures on October 26, 2020 (the “Maturity Date”). Neither interest nor principal payment are due until the Maturity Date, subject to earlier conversion. QNAH may elect to convert all or any portion of the outstanding principal balance of the Note and all unpaid accrued interest thereon at any time prior to the Maturity Date into shares of the Company’s common stock at a conversion price of $3.984 per share. Debt issuance costs of $25,787 and $40,510 relating to the QNAH Convertible Note are being presented as a direct reduction of Convertible Note, related party – net of debt issuance costs as of December 31, 2018 and December 31, 2017, respectively. Amortization of the QNAH Convertible Note deferred financing costs was $13,454 and $1,269 for the years ended December 31, 2018 and 2017, respectively. Interest accrued on the QNAH Convertible Note for the years ended December 31, 2018 and 2017 was $90,000 and $8,630, respectively. Both amounts were included in interest expense in the accompanying consolidated statements of operations.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 17. Subsequent Events On February 15, 2019, the Company and QML entered into a fourth amendment of SOW Two (see Note 16), effective as of February 5, 2019 (such amendment, the “Fourth SOW Two Amendment”). The Fourth SOW Two Amendment contemplates the use of the IUO assay developed in the previous phases of SOW Two in multiple biopharmaceutical company partner clinical trials and additional development activities which potentially could be included in a future companion diagnostic regulatory submission. The development activities to be performed under the Fourth SOW Two Amendment are expected to be completed by the end of 2019. QML has agreed to pay the Company development fees in the low, single-digit millions of dollars for the additional assay development activities. In addition, the Company and QML will share in any net profits (as determined under the Governing Agreement) generated by this development work.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Principles of Consolidation	Principles of Consolidation The Company formed a French subsidiary, HTG Molecular Diagnostics France SARL (“HTG France”), in November 2018. The consolidated financial statements include the accounts of the Company and this wholly owned subsidiary after elimination of intercompany transactions and balances as of December 31, 2018.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, bonus accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with financial institutions, commercial paper, money market instruments and high credit quality corporate debt securities purchased with a term of three months or less.
Accounts Receivable	Accounts Receivable Accounts receivable represent valid claims against debtors. Management reviews accounts receivable regularly to determine, using the specific identification method, if any receivable amounts will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value.
Investments	Investments The Company classifies its debt securities as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive loss, net of tax. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, are included in other income (expense) within the accompanying consolidated statements of operations. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Interest earned on all securities is included in other income (expense) within the accompanying consolidated statements of operations. Investments in securities with maturities of less than one year, or where management’s intent is to use the investments to fund current operations, or to make them available for current operations, are classified as short-term investments. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are charged against other income (expense).
Restricted Cash	Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts shown in the accompanying consolidated statements of cash flows. December 31, 2018 Cash and cash equivalents $ 8,432,600 Restricted cash - non-current 3,270,247 Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 11,702,847 Amounts included in restricted cash represent those required to be set aside in escrow under the terms of the MidCap Term Loan (see Note 8) to collateralize the payment that will be due upon maturity of the QNAH Convertible Note (see Note 16). The amounts will be released to the Company upon subsequent delivery of subordination documents for the QNAH Convertible Note to MidCap or conversion of the QNAH Convertible Note. If neither occurs, the amounts will be applied by the escrow agent to repay in full the QNAH Convertible Note at maturity (or in connection with a prepayment at the direction of the Company) subject to the terms of the MidCap Term Loan.
Contract Assets	Contract Assets Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer, for which rights to payment are conditional upon something other than the passage of time.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date. Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the MidCap Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt securities with similar terms and risk characteristics. In October 2017, the Company received $3.0 million in gross proceeds from, and issued a subordinated convertible promissory note (the “QNAH Convertible Note”) in that principal amount to, QIAGEN North American Holdings, Inc. (“QNAH”). As of December 31, 2018, the estimated aggregate fair value of the QNAH Convertible Note is approximately $3.1 million, based on a discounted cash flow approach and utilizing an option pricing model to value the conversion feature, with key assumptions including expected volatility, discount rates, term and risk-free rates. The NuvoGen obligation is an obligation relating to an asset purchase transaction with a then-common stockholder of the Company. As of December 31, 2018, the estimated aggregate fair value of the NuvoGen obligation is approximately $6.0 million, determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates. The estimated fair values of the QNAH Convertible Note and the NuvoGen obligation represent Level 3 measurements.
Inventory, net	Inventory, net Inventory, consisting of raw materials, work in process and finished goods, is stated at the lower of cost (first-in, first-out) or net realizable value. Cost is determined using a standard cost system, whereby the standard costs are updated periodically to reflect current costs and net realizable value represents the lower of replacement cost or estimated net realizable value. The Company reserves or writes down its inventory for estimated obsolescence or inventory in excess of reasonably expected near term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. The period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may need to be extended beyond that period. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent rental agreement with the Company after evaluating the product for one year, the equipment is returned to the Company or the customer is allowed to continue use of the equipment, in which case the equipment is written off to selling, general and administrative expense in the accompanying consolidated statements of operations. HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Finished goods inventory under evaluation as of December 31, 2018 was $143,271 compared to $53,365 as of December 31, 2017.
Property and Equipment, net	Property and Equipment, net Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method. Equipment used in the field is amortized using the straight-line method over the lesser of the period of the related reagent rental or collaborative development services agreement where applicable or the estimated useful life. Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life. Certain leasehold improvements constructed by the landlord of the Company’s Tucson, AZ facilities as an incentive for the Company to extend its leases are included in leasehold improvements in the consolidated balance sheets as of December 31, 2018. The total cost of the improvements constructed by the landlord of $710,000 was capitalized when construction was completed in February 2016 and is being amortized over the remaining term of the lease agreement. The incentive of $710,000 has been recognized as deferred rent within other current liabilities and other liabilities on the consolidated balance sheets and is being accreted over the lease term as a reduction of rent expense (see Note 14). Costs incurred in the development and installation of software for internal use and in the development of the Company’s website are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed). Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to the estimated undiscounted future cash flows expected to be generated by the asset group. If the carrying amount of an asset group exceeds its estimated future cash flow, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Although the Company has accumulated losses since inception, the Company believes the future cash flows will be sufficient to exceed the carrying value of the Company’s long-lived assets. There were no impairments of long-lived assets during the years ended December 31, 2018 and 2017.
Debt Issuance Costs and Debt Discounts	Debt Issuance Costs and Debt Discounts Costs incurred to issue non-revolving debt instruments are recognized as a reduction to the related debt balance in the accompanying consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Costs incurred to issue revolving debt instruments are deferred as an asset in the accompanying consolidated balance sheets and amortized on a straight-line basis to interest expense over the term of the revolving commitment .
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs represent legal and other direct costs related to planned future stock offering transactions. Deferred offering costs of $59,030 included as non-current assets in the accompanying consolidated balance sheets represent legal costs incurred during the year ended December 31, 2018 by the Company in contemplation of the issuance of additional shares in a future financing transaction. There were deferred offering costs of $2,953 included in the accompanying consolidated balance sheets as of December 31, 2017. Should the planned stock offering transactions prove to be unsuccessful, these deferred offering costs, as well as any additional expenses to be incurred, will be charged to selling, general and administrative expense in the consolidated statements of operations.
Contract Liabilities	Contract Liabilities Contract liabilities represent cash receipts for products or services to be delivered in future periods, including up-front fees received relating to custom RUO assay design and sample processing services and collaboration development services. When products or services are delivered to customers, contract liabilities are recognized as earned. Up-front fees received for custom RUO assay design or collaborative development services are recognized over time based on the costs incurred to date compared to total expected costs as design or development procedures are completed and outputs are produced.
Revenue Recognition	Revenue Recognition The Company adopted the Financial Accounting Standards Board (“FASB”) new revenue standard, Accounting Standards Codification 606, Revenue from Contracts with Customers For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. The Company has made a policy election to exclude from the measurement of the transaction price all taxes assessed by a government authority that are both imposed on and concurrent with a specific revenue producing transaction and collected by the Company from a customer. Such taxes may include but are not limited to sales, use, value added and certain excise taxes. See Note 9 for additional discussion of the Company’s revenue recognition policies.
Product Warranty	Product Warranty The Company generally provides a one-year warranty on its HTG EdgeSeq systems covering the performance of system hardware and software in conformance with customer specifications under normal use and protecting against defects in materials and workmanship. The Company may, at its option, replace, repair or exchange products covered under valid warranty claims. A provision for estimated warranty costs is recognized at the time of sale, through cost of product and product-related services revenue, based upon recent historical experience and other relevant information as it becomes available. The Company continuously assesses the adequacy of its product warranty accrual by reviewing actual claims and adjusts the provision as needed.
Research and Development Expenses	Research and Development Expenses Research and development expenses represent costs incurred internally for research and development activities and costs incurred externally to fund research activities. These costs include those generated through research and development efforts for the improvement and expansion of the Company’s proprietary technology and product offerings as well as those related to third-party collaborative development agreements, for which related revenue is included in collaborative development services revenue in the accompanying consolidated statements of operations. See for further discussion of the development costs associated with collaborative development services agreements included in research and development expense as compared to cost of revenue in the accompanying consolidated statements of operations.
Advertising	Advertising All costs associated with advertising and promotions are expensed as incurred. Advertising expense was $110,591 and $245 for the years ended December 31, 2018 and 2017, respectively, and is included as a component of selling, general and administrative expenses on the accompanying consolidated statements of operations.
Stock-based Compensation	Stock-based Compensation The Company incurs stock-based compensation expense relating to grants under its equity incentive plans of restricted stock units (“RSUs”) and stock options to employees, consultants and non-employee directors, and stock purchase rights granted under its employee stock purchase plan (“ESPP”). The Company recognizes expense for stock-based awards to employees and non-employee directors based on the fair value of awards on the date of grant. The fair value of RSUs is based on the quoted market price of the Company’s common stock on the date of grant. The fair value of ESPP rights and stock options granted pursuant to the Company’s equity incentive plans is estimated on the date of grant using the Black-Scholes option pricing model. The determination of the fair value utilizing the Black-Scholes option pricing model is affected by the fair value of the Company’s stock price and several assumptions, including volatility, expected term, risk-free interest rate, and dividend yield. Generally, these assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. The Company elected to change its policy surrounding forfeitures of equity awards with the adoption of the guidance in ASU No. 2016-09 on January 1, 2017. The Company no longer estimates the number of awards expected to be forfeited but instead accounts for such forfeitures as they occur. For stock-based awards to consultants, the fair value of the stock-based award is used to measure the transaction, as the Company believes this to be a more reliable measure of fair value than the services received. The fair value of each award is remeasured at each measurement date until performance by the nonemployee is complete. Stock-based compensation to nonemployees is recognized as expense over the requisite service period, which is generally the vesting period for awards, on a straight-line basis.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts and tax base of assets and liabilities using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established against net deferred tax assets for the uncertainty it presents of our ability to use the net deferred tax assets, in this case, primarily carryforwards of net operating tax losses and research and development tax credits. In assessing the realizability of net deferred tax assets we have assessed the likelihood that net deferred tax assets will be recovered from future taxable income, and to the extent that recovery is not “more likely than not” or there is an insufficient history of operating profits, a valuation allowance is established. We record the valuation allowance in the period we determine that it is not more likely than not that net deferred tax assets will be realized. For the years ended December 31, 2018 and 2017, we have provided a full valuation allowance for all net deferred tax assets due to their current realization being considered remote in the near term. Uncertain tax positions taken or expected to be taken in a tax return are accounted for using the more likely than not threshold for financial statement recognition and measurement. The Tax Cuts and Jobs Act (the “Tax Act”), which was signed into law on December 22, 2017, significantly revised the Internal Revenue Code of 1986, as amended (the “IRC”). For further information as to its impact on our financial statements see “Note 15. Income Taxes” in Part II, Item 8, Notes to Financial Statements.
Foreign Currency Translation and Foreign Currency Transactions	Foreign Currency Translation and Foreign Currency Transactions The Company has assets and liabilities, including accounts receivable and accounts payable, which are denominated in currencies other than its functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency gain (loss) within the consolidated statements of operations. Adjustments resulting from translating foreign functional currency financial statements of the Company’s wholly owned subsidiary into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the accompanying consolidated statements of stockholder’s equity (deficit).
Comprehensive Loss	Comprehensive Loss Comprehensive loss includes certain changes in equity that are excluded from net loss. Specifically, unrealized gains and losses on short and long-term available-for-sale investments and adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in comprehensive loss.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom RUO panel design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The top three customers accounted for 58%, 10% and 9% of the Company’s revenue for the year ended December 31, 2018, compared with 54%, 8% and 6% for the year ended December 31, 2017. The largest three customers accounted for approximately 44%, 27%, and 11% of the Company’s net accounts receivable as of December 31, 2018. The accounts receivable primarily relate to sample processing services performed for two biopharmaceutical company customers and work performed under the Company’s Governing Agreement with QML. The largest two customers accounted for approximately 66% and 11% of the Company’s net accounts receivable at December 31, 2017. Three vendors accounted for 24%, 14% and 11% of the Company’s accounts payable as of December 31, 2018 primarily related to the Company’s collaborative development services programs compared to 23%, 17% and 15% of the Company’s accounts payable at December 31, 2017. The Company currently relies on a single supplier to supply a subcomponent used in the HTG EdgeSeq processors. A loss of this supplier could significantly delay the delivery of products, which in turn would materially affect the Company’s ability to generate revenue.
Recently Adopted and New Accounting Pronouncements	Recently Adopted Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In March 2016, the FASB issued ASU No. 2016-08, Revenue Recognition: Clarifying the new Revenue Standard’s Principal-Versus-Agent Guidance In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients. The new revenue standard and the standards that amend it were effective for public entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company adopted ASC 606 as of January 1, 2018 using the full retrospective approach. The adoption of ASC 606 did not have a material impact on 2017 revenue recognition or on opening equity, as the timing and measurement of revenue recognition is materially the same for the Company as under ASC 605, Revenue Recognition In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting New Accounting Pronouncements The following are new FASB ASUs that had not been adopted by the Company as of December 31, 2018, and are grouped by their respective effective dates: January 1, 2019 In February 2016, the FASB issued ASU No. 2016-02, Leases, In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting January 1, 2020 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In November 2018, the FASB issued ASU No. 2018-18, which amended ASC 808, Collaborative Arrangements Revenue from Contracts with Customers .

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts shown in the accompanying consolidated statements of cash flows. December 31, 2018 Cash and cash equivalents $ 8,432,600 Restricted cash - non-current 3,270,247 Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 11,702,847

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the date indicated: December 31, 2018 2017 Raw materials $ 892,631 $ 984,328 Work in process 168,937 66,314 Finished goods 284,444 192,021 Total gross inventory 1,346,012 1,242,663 Less inventory allowance (39,403 ) (62,142 ) $ 1,306,609 $ 1,180,521

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at December 31, 2018 and 2017, respectively, in the fair value hierarchy: Balance at December 31, 2018 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 6,923,255 $ 998,400 $ — $ 7,921,655 Investments available-for-sale at fair value U.S. government obligations 6,031,515 — — 6,031,515 Corporate debt securities — 16,649,534 — 16,649,534 Total $ 12,954,770 $ 17,647,934 $ — $ 30,602,704 Balance at December 31, 2017 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 8,521,054 $ — $ — $ 8,521,054 Total $ 8,521,054 $ — $ — $ 8,521,054

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	12 Months Ended
	Dec. 31, 2018
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The Company’s portfolio of available-for-sale securities consists of U.S. Treasuries and high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities at December 31, 2018: December 31, 2018 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 6,032,844 $ — $ (1,329 ) $ 6,031,515 Corporate debt securities 16,650,513 — (979 ) 16,649,534 Total available-for-sale securities $ 22,683,357 $ — $ (2,308 ) $ 22,681,049
Summary of Contractual Maturities of Debt Investment Securities	Contractual maturities of debt investment securities at December 31, 2018 are shown below. Under 1 Year 1 to 2 Years Total U.S. Treasury securities $ 6,031,515 $ — $ 6,031,515 Corporate debt securities 16,649,534 — 16,649,534 Total available-for-sale securities $ 22,681,049 $ — $ 22,681,049
Summary of Debt Securities with Unrealized Losses	The following table shows the gross unrealized losses and fair values of the Company’s investments that have unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of December 31, 2018: Under 1 Year 1 to 2 Years Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses U.S. Treasury securities $ 6,031,515 $ (1,329 ) $ — $ — $ 6,031,515 $ (1,329 ) Corporate debt securities 1,201,308 (979 ) — — 1,201,308 (979 ) Total available-for-sale securities with unrealized losses $ 7,232,823 $ (2,308 ) $ — $ — $ 7,232,823 $ (2,308 )

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net consists of the following: December 31, 2018 2017 Furniture & fixtures $ 791,973 $ 582,007 Leasehold improvements 1,930,300 1,863,698 Equipment used in manufacturing 2,297,797 1,963,558 Equipment used in research & development 1,456,954 1,328,556 Equipment used in the field 125,253 130,552 Software 373,683 373,683 Construction in progress 19,246 255,641 6,995,206 6,497,695 Less: accumulated depreciation and amortization (4,621,416 ) (3,192,805 ) $ 2,373,790 $ 3,304,890

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consist of the following: December 31, 2018 2017 Accrued employee bonuses $ 2,150,418 $ 3,049,109 Payroll and employee benefit accruals 698,969 369,275 Accrued professional fees 60,400 101,150 Accrued interest 156,492 45,544 Other accrued liabilities 292,186 181,708 $ 3,358,465 $ 3,746,786

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	Dec. 31, 2018
Revenue From Contract With Customer [Abstract]
Product and Product-Related Service Revenue from Sale of Instruments and Consumables	Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the years ended December 31, 2018 and 2017 as follows: Years Ended December 31, 2018 2017 Product revenue: Instrument $ 351,885 $ 385,143 Consumables 1,964,499 1,463,347 Total product revenue 2,316,384 1,848,490 Product-related services revenue: Custom RUO assay design 964,241 419,515 Sample processing 5,840,765 4,529,250 Total product-related services revenue 6,805,006 4,948,765 Total product and product-related services revenue $ 9,121,390 $ 6,797,255
Schedule of Collaborative Development Services	Collaborative Development Services Revenue Years Ended December 31, 2018 2017 Collaborative development services $ 12,382,504 $ 7,962,312
Schedule of Changes in Contract Liability	Changes in the Company’s contract liability were as follows as of the date indicated: Product Revenue Custom RUO Assay Design Sample Processing Collaborative Development Services Total Contract Liability Balance at January 1, 2018 $ 39,426 $ 197,606 $ 490,536 $ 110,317 $ 837,885 Deferral of revenue 190,703 448,580 197,541 70,918 907,742 Customer deposits 131,864 — — — 131,864 Recognition of deferred Revenue (245,446 ) (596,186 ) (443,677 ) (181,235 ) (1,466,544 ) Balance at December 31, 2018 $ 116,547 $ 50,000 $ 244,400 $ — $ 410,947

Other Agreements (Tables)

Other Agreements (Tables)	12 Months Ended
	Dec. 31, 2018
Other Agreements [Abstract]
Schedule of Remaining Minimum Principal Payments Due	Minimum payments to be made in 2019 include $363,686 of revenue-based payments payable as of December 31, 2018 and an estimate of additional revenue-based payments to be made throughout the remainder of 2019 relating to revenue generated in the first, second and third quarters of 2019 using actual revenue generated in the same quarters in 2018. Minimum payments for the remaining years include only the minimum payments for each year. Actual payments could be significantly more than provided in the table, to the extent that 6% of the Company’s annual revenue in 2020 and beyond exceeds $400,000: 2019 $ 1,290,234 2020 400,000 2021 400,000 2022 400,000 2023 400,000 2024 and beyond 3,996,387 Total NuvoGen obligation payments 6,886,621 Plus interest accretion 106,132 Total NuvoGen obligation, net $ 6,992,753

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Years Ended December 31, 2018 2017 Numerator: Net loss $ (16,453,918 ) $ (18,960,017 ) Denominator: Weighted-average shares outstanding-basic and diluted 27,523,463 10,597,318 Net loss per share, basic and diluted $ (0.60 ) $ (1.79 )
Outstanding Options, Warrants, Restricted Stock Units and Debt Conversion Option Excluded from Computation of Diluted Net Loss per Share	The following outstanding options, warrants, restricted stock units and debt conversion option were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Years Ended December 31, 2018 2017 Options to purchase common stock 2,047,237 1,517,771 Common stock warrants 237,846 219,723 Restricted stock units 227,707 26,666 QNAH convertible note 777,769 755,178

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Summary of Outstanding Warrants	The following table shows the common stock warrants outstanding as of December 31, 2018: Shares of Common Underlying Warrants Exercise Price/Share Expiration Date 28,713 $ 23.51 2024 144,772 14.00 2022 931 6.45 2019 45,307 2.76 2026 18,123 7.73 2028

Stockholders Deficit (Tables)

Stockholders Deficit (Tables)	12 Months Ended
	Dec. 31, 2018
Summary of Stock-Based Compensation	The Company incurs stock-based compensation expense relating to the grants under its equity incentive plans of RSUs and stock options to employees, non-employee directors and consultants of the Company and its affiliates and through its employee stock purchase plan. Amounts recognized in the accompanying consolidated statements of operations with respect to the Company’s stock-based compensation and employee stock purchase plan were as follows: Years Ended December 31, 2018 2017 Selling, general and administrative $ 1,709,945 $ 1,012,253 Research and development 172,005 319,916 Cost of product and product-related services revenue 65,064 103,918 $ 1,947,014 $ 1,436,087
Summary of Stock Option Plans Activity	The following table summarizes stock option activity during the two-year period ended December 31, 2018: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at January 1, 2017 1,161,705 $ 3.35 7.7 $ 36,887 Granted 494,500 2.09 Exercised (41,815 ) 2.68 $ 152,130 Forfeited (81,676 ) 2.64 Expired/Cancelled (14,943 ) 6.15 Balance at December 31, 2017 1,517,771 $ 2.97 7.5 $ 67,242 Granted 802,500 3.39 Exercised (144,645 ) 2.19 $ 243,531 Forfeited (66,428 ) 3.24 Expired/Cancelled (61,961 ) 6.52 Balance at December 31, 2018 2,047,237 $ 3.07 7.6 $ 366,007 Vested and expected to vest at December 31, 2018 2,047,237 $ 3.07 7.6 $ 366,007 Exercisable at December 31, 2017 851,996 $ 3.31 6.5 $ 248 Exercisable at December 31, 2018 1,256,352 $ 2.91 6.5 $ 346,595
Summary of Material Factors Incorporated in Black-Scholes Model In Estimating Fair Value of Options Granted	The material factors incorporated in the Black-Scholes model in estimating the fair value of the stock options granted for the periods presented were as follows: 2018 2017 Fair value of common stock $3.26 - 5.06 $1.71 - 3.46 Risk-free interest rate 2.59% - 2.82% 1.75% - 2.20% Expected volatility 79.5% - 85.8% 58.5% - 62.6% Expected term 5.3 to 5.5 years 5.1 to 6.3 years Expected dividend yield 0% 0%
Summary of Restricted Stock Unit (“RSU”) Plans Activity	The following table summarizes RSU award activity during the two-year period ended December 31, 2018: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at January 1, 2017 355,499 $ 2.41 Granted 10,000 1.75 Vested (336,333 ) 2.47 Forfeited (2,500 ) 2.46 Balance at December 31, 2017 26,666 $ 2.78 Granted 492,051 3.63 Released (291,010 ) 3.72 Balance at December 31, 2018 227,707 $ 3.30 Vested and unissued at December 31, 2018 13,126 $ 3.40
Employee Stock Purchase Plan
Summary of Material Factors Incorporated in Black-Scholes Model In Estimating Fair Value of Options Granted	The material factors incorporated in the Black-Scholes model in estimating the fair value of the ESPP awards for the periods presented were as follows: 2018 2017 Fair value of common stock $1.85 - 4.00 $2.11 - 3.17 Risk-free interest rate 1.88% - 2.07% 0.61% - 1.12% Expected volatility 83.2% - 85.8% 68.0% - 70.0% Expected term 0.5 years 0.5 years Expected dividend yield 0% 0%

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Minimum Facility Lease Payments Before Common Area Maintenance Charges	The Company’s annual minimum lease payments relating to its Tucson and Sausheim facilities leases before common area maintenance charges are as follows as of December 31, 2018: 2019 $ 525,745 2020 528,225 2021 53,907 2022 10,768 2023 10,768 2024 and beyond 43,073 $ 1,172,486
Summary of Product Warranty Liability	The following is a summary of the Company’s general product warranty liability, which is included in accrued liabilities in the accompanying consolidated balance sheets for the years ended December 31, 2018 and 2017: Years Ended December 31. 2018 2017 Beginning balance $ 37,156 $ 50,426 Cost of warranty claims (2,596 ) (9,814 ) Increase in warranty reserve 28,901 (3,456 ) Ending balance $ 63,461 $ 37,156

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Components of Income Tax Expense	The components of income tax expense are as follows: Years Ended December 31, 2018 2017 Current: Federal $ — $ — State 3,526 2,921 Total current income tax expense $ 3,526 $ 2,921 Deferred: Federal $ — $ — State — — Total deferred income tax expense $ — $ — Total income tax expense $ 3,526 $ 2,921
Schedule of Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes	The Company’s actual income tax expense for the years ended December 31, 2018 and 2017 differ from the expected amount computed by applying the statutory federal income tax rate to loss before income taxes as follows: Years Ended December 31, 2018 2017 Computed tax (benefit) at statutory rate (2018: 21%, 2017: 34%) $ (3,454,582 ) $ (6,445,413 ) State taxes, net of federal benefit (384,035 ) (532,952 ) Stock-based compensation 82,024 231,396 Foreign tax rate differential (3,158 ) — Return to provision (31,111 ) (15,375 ) Other 51,598 20,292 Research and development tax credit - state (511,845 ) (576,525 ) Research and development tax credit - federal (506,364 ) (440,058 ) Federal rate change on deferred items as of enactment date — 16,232,211 Uncertain tax position adjustment for prior periods 1,029,115 — Increase (decrease) in valuation allowance 3,731,884 (8,470,655 ) $ 3,526 $ 2,921
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities comprise the following: Years Ended December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 33,431,082 $ 29,475,597 Research and development credits 3,076,441 3,114,091 Deferred revenue 86,567 204,061 Inventory reserve 9,645 15,134 Fixed assets and intangibles 223,767 147,395 Accrued NuvoGen liability 1,720,335 1,952,567 Accrued expense 86,034 24,500 Other 106,913 74,986 38,740,784 35,008,331 Valuation allowance (38,740,784 ) (35,008,331 ) Deferred tax asset, net $ — $ —
Summary of Federal Net Operating Loss Carryforwards	The Company’s federal NOL carryforwards have the following expiration dates: Year of Expiration Carryforwards Federal NOL carryforwards 2021 $ 211,806 2023 1,635,651 2024 1,217,290 2025 1,409,498 2026 1,175,594 2027 1,676,458 2028 3,037,785 2029 3,753,314 2030 623,235 2031 5,435,312 2032 10,913,787 2033 12,095,966 2034 14,190,409 2035 21,112,183 2036 24,302,042 2037 18,986,265 2038 16,983,240 $ 138,759,835
Schedule of Reconciliation of Gross Unrecognized Tax Benefits	A reconciliation of the Company’s gross unrecognized tax benefits is as follows: Years Ended December 31, 2018 2017 Balance at beginning of year $ — $ — Increases to prior positions 1,029,115 Increases for current year positions 509,105 — Balance at end of year $ 1,538,220 $ —

Description of Business, Basi_2

Description of Business, Basis of Presentation and Principles of Consolidation - Additional Information (Details) - Segment	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Significant Accounting Policies [Line Items]
Number of operating segments	1
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage	69.00%	71.00%
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States | QIAGEN Manchester Limited | Collaborative Development Services
Significant Accounting Policies [Line Items]
Sales revenue percentage	84.00%	76.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	Jan. 01, 2019USD ($)	Oct. 31, 2017USD ($)	Dec. 31, 2018USD ($)CustomerVendor	Dec. 31, 2017USD ($)CustomerVendor	Dec. 31, 2016USD ($)	Feb. 29, 2016USD ($)
Significant Accounting Policies [Line Items]
Maturity period of investments			less than one year
Finished goods inventory			$ 284,444	$ 192,021
Leasehold improvements					$ 710,000	$ 710,000
Impairment of Long-lived assets			0	0
Deferred offering costs, current			59,030	2,953
Advertising and promotion expense incurred			$ 110,591	$ 245
Supplier Concentration Risk | Accounts Payable
Significant Accounting Policies [Line Items]
Number of vendors | Vendor			3	3
Supplier Concentration Risk | Accounts Payable | Vendor One
Significant Accounting Policies [Line Items]
Sales revenue percentage			24.00%	23.00%
Supplier Concentration Risk | Accounts Payable | Vendor Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			14.00%	17.00%
Supplier Concentration Risk | Accounts Payable | Vendor Three
Significant Accounting Policies [Line Items]
Sales revenue percentage			11.00%	15.00%
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer			3	3
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage			58.00%	54.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			10.00%	8.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage			9.00%	6.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer			3	2
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage			44.00%	66.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			27.00%	11.00%
Accounts Receivable | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage			11.00%
Software and Software Development Costs
Significant Accounting Policies [Line Items]
Long-term asset, estimated life			3 years
Minimum
Significant Accounting Policies [Line Items]
Period of time customers use to evaluate the Company’s equipment			90 days
Long-term asset, estimated life			3 years
Maximum
Significant Accounting Policies [Line Items]
Period of time customers use to evaluate the Company’s equipment			180 days
Long-term asset, estimated life			5 years
Maximum | Accounting Standards Update 2016-02 | Office and Equipment Leases | Subsequent Event
Significant Accounting Policies [Line Items]
Gross-up amount of leases effect in balance sheets	$ 1,500,000
NuvoGen Asset Purchase Agreement
Significant Accounting Policies [Line Items]
Convertible debt, fair value			$ 6,000,000
QIAGEN North American Holdings, Inc.
Significant Accounting Policies [Line Items]
Convertible debt, fair value			3,100,000
QIAGEN North American Holdings, Inc. | Convertible Promissory Note
Significant Accounting Policies [Line Items]
Gross proceeds from issuance of subordinated notes		$ 3,000,000
HTG EdgeSeq
Significant Accounting Policies [Line Items]
Finished goods inventory			$ 143,271	$ 53,365

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 8,432,600	$ 9,968,600
Restricted cash - non-current	3,270,247
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 11,702,847

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 892,631	$ 984,328
Work in process	168,937	66,314
Finished goods	284,444	192,021
Total gross inventory	1,346,012	1,242,663
Less inventory allowance	(39,403)	(62,142)
Inventory, net	$ 1,306,609	$ 1,180,521

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Reserve for shrinkage and excess inventory	$ 39,403	$ 62,142
Net change in inventory valuation reserves	22,739	208,165
Provision for excess inventory	$ 83,218	$ 366,963

Fair Value - Financial Assets a

Fair Value - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Asset included in:
Investments available-for-sale at fair value	$ 22,681,049	$ 0
U.S. Government Obligations
Asset included in:
Investments available-for-sale at fair value	6,031,515
Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	16,649,534
Fair Value, Measurements, Recurring
Asset included in:
Financial Assets	30,602,704	8,521,054
Fair Value, Measurements, Recurring | Money Market Securities
Asset included in:
Cash and cash equivalents	7,921,655	8,521,054
Fair Value, Measurements, Recurring | U.S. Government Obligations
Asset included in:
Investments available-for-sale at fair value	6,031,515
Fair Value, Measurements, Recurring | Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	16,649,534
Fair Value, Measurements, Recurring | Level 1
Asset included in:
Financial Assets	12,954,770	8,521,054
Fair Value, Measurements, Recurring | Level 1 | Money Market Securities
Asset included in:
Cash and cash equivalents	6,923,255	$ 8,521,054
Fair Value, Measurements, Recurring | Level 1 | U.S. Government Obligations
Asset included in:
Investments available-for-sale at fair value	6,031,515
Fair Value, Measurements, Recurring | Level 2
Asset included in:
Financial Assets	17,647,934
Fair Value, Measurements, Recurring | Level 2 | Money Market Securities
Asset included in:
Cash and cash equivalents	998,400
Fair Value, Measurements, Recurring | Level 2 | Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	$ 16,649,534

Fair Value - Additional Informa

Fair Value - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0	$ 0

Available-for-Sale Securities -

Available-for-Sale Securities - Summary of Available-for-sale Securities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 22,683,357
Gross Unrealized Losses	(2,308)
Fair Value (Net Carrying Amount)	22,681,049	$ 0
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	6,032,844
Gross Unrealized Losses	(1,329)
Fair Value (Net Carrying Amount)	6,031,515
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	16,650,513
Gross Unrealized Losses	(979)
Fair Value (Net Carrying Amount)	$ 16,649,534

Available-for-Sale Securities_2

Available-for-Sale Securities - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Investments Debt And Equity Securities [Abstract]
Available for sale securities	$ 22,681,049	$ 0
Unrealized gain on short and long-term investments	(2,308)	$ 1,090
Other-than-temporary impairment	$ 0

Available-for-Sale Securities_3

Available-for-Sale Securities - Summary of Contractual Maturities of Debt Investment Securities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	$ 22,681,049
Fair Value (Net Carrying Amount)	22,681,049	$ 0
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	6,031,515
Fair Value (Net Carrying Amount)	6,031,515
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	16,649,534
Fair Value (Net Carrying Amount)	$ 16,649,534

Available-for-Sale Securities_4

Available-for-Sale Securities - Summary of Debt Securities with Unrealized Losses (Details)	Dec. 31, 2018USD ($)
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	$ 7,232,823
Under 1 Year, Gross Unrealized Losses	(2,308)
Total, Fair Value	7,232,823
Total, Gross Unrealized Losses	(2,308)
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	6,031,515
Under 1 Year, Gross Unrealized Losses	(1,329)
Total, Fair Value	6,031,515
Total, Gross Unrealized Losses	(1,329)
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	1,201,308
Under 1 Year, Gross Unrealized Losses	(979)
Total, Fair Value	1,201,308
Total, Gross Unrealized Losses	$ (979)

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Furniture & fixtures	$ 791,973	$ 582,007
Leasehold improvements	1,930,300	1,863,698
Equipment used in manufacturing	2,297,797	1,963,558
Equipment used in research & development	1,456,954	1,328,556
Equipment used in the field	125,253	130,552
Software	373,683	373,683
Construction in progress	19,246	255,641
Total property and equipment, gross	6,995,206	6,497,695
Less: accumulated depreciation and amortization	(4,621,416)	(3,192,805)
Property and equipment, net	$ 2,373,790	$ 3,304,890

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Depreciation and leasehold improvement amortization expense	$ 1,468,121	$ 1,241,873

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Payables And Accruals [Abstract]
Accrued employee bonuses	$ 2,150,418	$ 3,049,109
Payroll and employee benefit accruals	698,969	369,275
Accrued professional fees	60,400	101,150
Accrued interest	156,492	45,544
Other accrued liabilities	292,186	181,708
Total accrued liabilities	$ 3,358,465	$ 3,746,786

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details)	Mar. 26, 2018USD ($)$ / sharesshares	Mar. 31, 2018USD ($)	Mar. 31, 2016USD ($)	Aug. 31, 2014USD ($)Institution	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016Institution	Jul. 11, 2018USD ($)
Debt Instrument [Line Items]
Debt instrument, amortization expense					$ (12,480)	$ 195,248
Repayment of outstanding principal and interest					4,276,988
Loss on extinguishment of Growth Term Loan					105,064
Revolving loan cost					67,068
MidCap Credit Facility
Debt Instrument [Line Items]
Debt instrument, amortization expense					$ 121,611
Credit facility aggregate principal amount	$ 20,000,000
Line of credit facility interest rate at the end of the period	9.60%
Line of credit facility, expiration period	36 months
Line of credit facility first anniversary early termination fee percentage	3.00%
Line of credit facility second anniversary early termination fee percentage	2.00%
Line of credit facility third anniversary early termination fee percentage	1.00%
Origination fee	$ 100,000
Line of credit facility termination fee	4.50%
Amount required to deposit in escrow account	$ 3,300,000
Escrow deposit								$ 3,300,000
Minimum amount in deposit account subject to control agreement	$ 20,000,000
Credit facility, covenant terms					Commencing with the calendar quarter ending on the later of (a) June 30, 2019 and (b) the last day of the calendar quarter in which MidCap Tranche 2 is funded, the Company must also comply with a financial covenant relating to trailing twelve-month minimum Net Revenue requirements (as defined in the MidCap Credit Facility), tested on a quarterly basis
Credit Facility increase in interest on obligation percentage	3.00%
Percentage of weighted average closing price	150.00%
Fair value of warrants	$ 74,000
Unamortized debt discount					$ 610,359
MidCap Credit Facility | MidCap Tranche 1
Debt Instrument [Line Items]
Credit facility aggregate principal amount	$ 7,000,000
Line of credit facility interest rate	7.25%
Credit facility, basis spread on variable rate	1.25%
Credit facility, basis spread on variable rate description	one-month LIBOR
Warrants to purchase of common stock expiration year	10 years
Warrants to purchase common stock, shares | shares	18,123
Warrants exercise price | $ / shares	$ 7.73
MidCap Credit Facility | MidCap Tranche 2
Debt Instrument [Line Items]
Credit facility aggregate principal amount	$ 13,000,000
Line of credit facility interest rate	7.25%
Credit facility, basis spread on variable rate	1.25%
Credit facility, basis spread on variable rate description	one-month LIBOR
Warrants to purchase of common stock expiration year	10 years
Percentage of warrants to purchase common stock	2.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility aggregate principal amount	$ 2,000,000
Line of credit facility interest rate	4.25%
Credit facility, basis spread on variable rate	1.25%
Credit facility, basis spread on variable rate description	one-month LIBOR
Line of credit facility first anniversary early termination fee percentage	3.00%
Line of credit facility second anniversary early termination fee percentage	2.00%
Line of credit facility third anniversary early termination fee percentage	1.00%
Credit facility outstanding amount					0
Credit facility origination fee percentage	0.50%
Credit facility, unused line fee percentage	0.50%
Credit facility collateral management fee percentage	0.50%
Credit facility minimum drawn balance percentage	20.00%
Revolving loan cost					67,068	0
Amortization of deferred financing costs					12,352
Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Credit facility additional borrowing capacity	$ 8,000,000
Growth Term Loan
Debt Instrument [Line Items]
Number of loan lending institutions | Institution				2			2
prepayment fee Percentage				1.00%
Debt instrument, amortization expense					62,951	404,462
Debt discount						$ 629,777
Repayment of outstanding principal and interest		$ 4,300,000
Loss on extinguishment of Growth Term Loan					105,064
Unamortized discounts					$ 67,272
Growth Term Loan A
Debt Instrument [Line Items]
Term loan payable				$ 11,000,000
Debt instrument, fixed rate				8.50%
Debt instrument, maturity date				Sep. 30, 2018
Growth Term Loan B
Debt Instrument [Line Items]
Term loan payable			$ 5,000,000
Debt instrument, fixed rate			8.75%
Debt instrument, maturity date			Sep. 30, 2018

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Product and Product-Related Service Revenue from Sale of Instruments and Consumables (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 21,503,894	$ 14,759,567
Product and Product-related Services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	9,121,390	6,797,255
HTG EdgeSeq | Instrument
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	351,885	385,143
HTG EdgeSeq | Consumables
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	1,964,499	1,463,347
HTG EdgeSeq | Product revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	2,316,384	1,848,490
HTG EdgeSeq | Custom RUO assay design
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	964,241	419,515
HTG EdgeSeq | Sample processing
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	5,840,765	4,529,250
HTG EdgeSeq | Product-related services revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	6,805,006	4,948,765
HTG EdgeSeq | Product and Product-related Services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 9,121,390	$ 6,797,255

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Agreements for product and product-related services revenue, description	The Company’s agreements for product and product-related services revenue have an expected duration of one year or less
Revenue	$ 21,503,894	$ 14,759,567
Contract liabilities	410,947	837,885
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Revenue	12,382,504	7,962,312
Contract liabilities		110,317
Collaborative Development Services | Diagnostic Development Services Agreements
Disaggregation Of Revenue [Line Items]
Revenue	$ 0	$ 25,000
Minimum
Disaggregation Of Revenue [Line Items]
Customer payment term	30 days
Maximum
Disaggregation Of Revenue [Line Items]
Customer payment term	90 days

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Additional Information1 (Details)	Dec. 31, 2018
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-01-01
Disaggregation Of Revenue [Line Items]
Agreements for product and product-related services revenue	1 year

Revenue from Contract with Cust

Revenue from Contract with Customer - Schedule of Collaborative Development Services (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Service revenue	$ 21,503,894	$ 14,759,567
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Service revenue	$ 12,382,504	$ 7,962,312

Revenue from Contract with Cu_2

Revenue from Contract with Customer - Schedule of Changes in Contract Liability (Details)	12 Months Ended
	Dec. 31, 2018USD ($)
Disaggregation Of Revenue [Line Items]
Balance at January 1, 2018	$ 837,885
Deferral of revenue	907,742
Customer deposits	131,864
Recognition of deferred Revenue	(1,466,544)
Balance at December 31, 2018	410,947
Product Revenue
Disaggregation Of Revenue [Line Items]
Balance at January 1, 2018	39,426
Deferral of revenue	190,703
Customer deposits	131,864
Recognition of deferred Revenue	(245,446)
Balance at December 31, 2018	116,547
Custom RUO Assay Design
Disaggregation Of Revenue [Line Items]
Balance at January 1, 2018	197,606
Deferral of revenue	448,580
Recognition of deferred Revenue	(596,186)
Balance at December 31, 2018	50,000
Sample Processing
Disaggregation Of Revenue [Line Items]
Balance at January 1, 2018	490,536
Deferral of revenue	197,541
Recognition of deferred Revenue	(443,677)
Balance at December 31, 2018	244,400
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Balance at January 1, 2018	110,317
Deferral of revenue	70,918
Recognition of deferred Revenue	$ (181,235)

Other Agreements - Additional I

Other Agreements - Additional Information (Details)	12 Months Ended
	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)
Other Agreements [Line Items]
Upfront consideration paid in exchange of common stock | shares	5,587
Asset purchase agreement fixed payments paid for first two years	$ 740,000
Asset purchase agreement aggregate cash compensation paid	15,000,000
Debt instrument, amortization expense	(12,480)	$ 195,248
Research and development	$ 12,598,034	9,996,627
Agreement expiration date	May 31, 2027
Description on termination of agreement	The Company may terminate the Restated Agreement at any time upon 90 days’ written notice and may terminate any development plan under the Restated Agreement upon 30 days’ prior written notice. Illumina may terminate the Restated Agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control, subject to a transition period of up to 12 months for then-ongoing development plans. Either party may terminate the Restated Agreement upon the other party’s material breach of the Restated Agreement that remains uncured for 30 days, or upon the other party’s bankruptcy.
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	$ 600,000
Research and development	$ 12,500	50,000
Agreement termination notice period	90 days
Development plan agreement termination notice period	30 days
Number of days material breach remains uncured	30 days
Measurement Input, Default Rate [Member]
Other Agreements [Line Items]
Discount rate used to calculate asset purchase obligation	2.5
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Percentage on annual revenues for cash consideration to be paid	6.00%
Asset purchase agreement yearly fixed fees paid	$ 400,000	800,000
Asset purchase agreement quarterly installments due from beginning 2018	400,000
Accrued revenue-based payments	0
Additional revenue based payments payable	$ 363,686	85,574
Percentage of compounded annual interest on unpaid Obligation	2.50%
NuvoGen
Other Agreements [Line Items]
Convertible notes and related debt discount	$ (106,132)	(118,612)
Debt instrument, amortization expense	$ (12,480)	$ 195,248

Other Agreements - Schedule of

Other Agreements - Schedule of Remaining Minimum Principal Payments Due (Details) - NuvoGen Asset Purchase Agreement	Dec. 31, 2018USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2,019	$ 1,290,234
2,020	400,000
2,021	400,000
2,022	400,000
2,023	400,000
2024 and beyond	3,996,387
Total NuvoGen obligation payments	6,886,621
Plus interest accretion	106,132
Total NuvoGen obligation, net	$ 6,992,753

Net Loss per Share - Reconcilat

Net Loss per Share - Reconcilation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Numerator:
Net loss	$ (16,453,918)	$ (18,960,017)
Denominator:
Weighted-average shares outstanding-basic and diluted	27,523,463	10,597,318
Net loss per share, basic and diluted	$ (0.60)	$ (1.79)

Net Loss per Share - Outstandin

Net Loss per Share - Outstanding Options, Warrants, Restricted Stock Units and Debt Conversion Option Excluded from Computation of Diluted Net Loss per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	2,047,237	1,517,771
Restricted Stock Units R S U
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	227,707	26,666
Warrants | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	237,846	219,723
QNAH convertible note
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	777,769	755,178

Warrants - Additional Informati

Warrants - Additional Information (Details)	Jan. 15, 2015USD ($)$ / sharesshares	Aug. 31, 2014Institution	Dec. 31, 2018$ / shares	Dec. 31, 2016Institution	Mar. 31, 2016$ / sharesshares	May 11, 2015$ / sharesshares	Aug. 22, 2014$ / sharesshares
Growth Term Loan
Class Of Warrant Or Right [Line Items]
Number of loan lending institutions | Institution		2		2
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares | shares					5,317	23,396	2,512,562
Warrants exercise price | $ / shares			$ 23.51		$ 23.51	$ 23.51	$ 0.2189
Warrants expiration date			Aug. 22, 2024
Common Stock Warrants one
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares | shares					45,307
Warrants exercise price | $ / shares			$ 6.45		$ 2.759
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares | shares	9,311,586
Warrants exercise price | $ / shares	$ 0.2189		$ 14
Warrants expiration date			Jan. 15, 2022
Aggregate consideration | $	$ 1,354
Convertible Note Warrants | IPO
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares | shares						144,772
Warrants exercise price | $ / shares						$ 14

Warrants -Summary of Outstandin

Warrants -Summary of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Mar. 31, 2016	May 11, 2015	Jan. 15, 2015	Aug. 22, 2014
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	144,772
Exercise Price/Share	$ 14			$ 0.2189
Expiration Date	2,022
Common Stock Warrants one
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	931
Exercise Price/Share	$ 6.45	$ 2.759
Expiration Date	2,019
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	45,307
Exercise Price/Share	$ 2.76
Expiration Date	2,026
Common Stock Tranche one
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	18,123
Exercise Price/Share	$ 7.73
Expiration Date	2,028
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	28,713
Exercise Price/Share	$ 23.51	$ 23.51	$ 23.51		$ 0.2189
Expiration Date	2,024

Stockholders Deficit - Addition

Stockholders Deficit - Additional Information (Details) - USD ($)	Jan. 01, 2019	Jan. 31, 2018	Jun. 30, 2017	Apr. 30, 2017	Jun. 30, 2018	Jan. 31, 2018	Jan. 31, 2017	Feb. 28, 2014	Mar. 31, 2018	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2016	May 11, 2015
Class Of Stock [Line Items]
Issuance of common stock from the ATM Offering, Shares									5,733,314
Gross proceeds from issuance of common stock									$ 21,100,000
Sales commission									600,000
Other offering expenses paid									200,000
Net proceeds from issuance of common stock									$ 20,200,000
Common stock, shares authorized										200,000,000		200,000,000		200,000,000	200,000,000
Common stock, par value										$ 0.001		$ 0.001		$ 0.001	$ 0.001
Common stock, shares issued										28,585,449		13,929,763		28,585,449	13,929,763
Common stock, shares outstanding										28,585,449		13,929,763		28,585,449	13,929,763
Common stock, voting rights														Each share of common stock is entitled to one vote.
Common stock, conversion features														The shares of common stock have no preemptive or conversion rights, no redemption or sinking fund provisions, no liability for further call or assessment, and are not entitled to cumulative voting rights.
Additional treasury stock														0	0
Preferred stock, shares authorized										10,000,000				10,000,000
Preferred stock, par value										$ 0.001				$ 0.001
Share based compensation arrangement by share based payment award, options, grants in period, weighted average grant date fair value														$ 2.29	$ 1.14
Accelerated vesting of stock options					46,613
Options extended exercise period					1 year
Incremental stock-based compensation expense														$ 79,400
Maximum aggregate number of common stock available purchase under employee stock purchase plan																250,000
Maximum number of shares that may be purchased by eligible participants under employee stock purchase plan																7,500
Stock issued under employee stock purchase plans														2,304	61,141
Two Thousand Fourteen Equity Incentive Plan
Class Of Stock [Line Items]
Shares reserved for issuance																		940,112
Number of shares available for issuance										0				0
Options granted in term														10 years
Two Thousand Fourteen Equity Incentive Plan | Subsequent Event
Class Of Stock [Line Items]
Number of additional shares registered for issuance	1,143,417
Stock-based Compensation | 2011 Equity Incentive Plan
Class Of Stock [Line Items]
Percentage of increase on outstanding shares								20.00%
Number of Shares, Granted								0
Employee Stock Option
Class Of Stock [Line Items]
Number of Shares, Granted														802,500	494,500
Unrecognized compensation expense										$ 1,675,285				$ 1,675,285
Compensation expense period expected to be recognized														3 years 14 days
Options to purchase common stock outstanding										2,047,237		1,517,771		2,047,237	1,517,771		1,161,705
Employee Stock Option | 2011 Equity Incentive Plan
Class Of Stock [Line Items]
Shares reserved for issuance																		14,006
Restricted Stock Units R S U
Class Of Stock [Line Items]
Share based compensation arrangement by share based payment award, options, grants in period, weighted average grant date fair value														$ 3.63	$ 1.75
Unrecognized compensation expense										$ 701,780				$ 701,780
Compensation expense period expected to be recognized														3 years 3 months 18 days
Vested and unissued RSU awards, description														Vested and unissued awards at December 31, 2018 represents RSU awards granted on August 16, 2018 for which the second vesting date was December 31, 2018, but for which issuance of awards occurred on the next business day, January 2, 2019.
Vested and unissued RSU awards granted date														Aug. 16, 2018
Vested and unissued RSU awards vesting date														Dec. 31, 2018
Vested and unissued RSU awards issuance date														Jan. 2, 2019
Board Of Directors
Class Of Stock [Line Items]
Retirement of treasury stock, shares							1,396
Board Of Directors | Two Thousand Fourteen Equity Incentive Plan | Minimum
Class Of Stock [Line Items]
Options exercise period														1 year
Board Of Directors | Two Thousand Fourteen Equity Incentive Plan | Maximum
Class Of Stock [Line Items]
Options exercise period														4 years
Underwritten Public Offering
Class Of Stock [Line Items]
Common stock price per share		$ 2.90				$ 2.90
Issuance of common stock from the ATM Offering, Shares						13,915,000
Net proceeds from initial public offering after underwriters' discounts, commissions and offering expenses						$ 37,700,000
Over-Allotment Option
Class Of Stock [Line Items]
Issuance of common stock from the ATM Offering, Shares						1,815,000
2014 Employee Stock Purchase Plan
Class Of Stock [Line Items]
Percentage of increase on outstanding shares														1.00%
Shares reserved for issuance										158,067				158,067
Vested and unissued RSU awards, description														The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year, from January 1, 2016 to January 1, 2024 by the least of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 195,000 shares, or (iii) a number determined by the Company’s board of directors that is less than (i) and (ii).
Maximum aggregate number of common stock available purchase under employee stock purchase plan										110,820				110,820
Common stock issuance offering date														Jan. 1, 2016
Common stock issuance expiration date														Jan. 1, 2024
Options to purchase common stock outstanding										195,000				195,000
Maximum contribution eligible compensation during a period to purchase common stock										15.00%				15.00%
Fair market value of company common stock, shares offering price														85.00%
Fair market value of company common stock, shares purchase price														85.00%
Common stock shares issued										35,805	4,176	39,969	39,972	39,993
Weighted average price per share			$ 1.79		$ 2.81					$ 1.57	$ 2.81	$ 1.61	$ 1.79	$ 1.57	$ 1.61
2014 Employee Stock Purchase Plan | Subsequent Event
Class Of Stock [Line Items]
Number of additional shares registered for issuance	195,000
Employee Stock Purchase Plan
Class Of Stock [Line Items]
Net proceeds from issuance of common stock														$ 9,997	$ 130,649
Common Stock
Class Of Stock [Line Items]
Issuance of common stock from the ATM Offering, Shares									300,000
Gross proceeds from issuance of common stock									$ 600,000
Stock issued under employee stock purchase plans														82,261	141,082
Sales Agreement
Class Of Stock [Line Items]
Common stock price per share				$ 0.001
Common stock aggregate offering price		$ 23,000,000	$ 40,000,000	$ 20,000,000

Stockholders Deficit - Summary

Stockholders Deficit - Summary of Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 1,947,014	$ 1,436,087
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	1,709,945	1,012,253
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	172,005	319,916
Cost of Product and Product-related Services Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 65,064	$ 103,918

Stockholders Deficit - Summar_2

Stockholders Deficit - Summary of Stock Option Plans Activity (Details) - Employee Stock Option - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance	1,517,771	1,161,705
Number of Shares, Granted	802,500	494,500
Number of Shares, Exercised	(144,645)	(41,815)
Number of Shares, Forfeited	(66,428)	(81,676)
Number of Shares, Expired/Cancelled	(61,961)	(14,943)
Number of Shares, Ending Balance	2,047,237	1,517,771	1,161,705
Number of Shares, Vested and expected to vest	2,047,237
Number of Shares, Exercisable	1,256,352	851,996
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 2.97	$ 3.35
Weighted-Average Exercise Price Per Share, Granted	3.39	2.09
Weighted-Average Exercise Price Per Share, Exercised	2.19	2.68
Weighted-Average Exercise Price Per Share, Forfeited	3.24	2.64
Weighted-Average Exercise Price Per Share, Expired/Cancelled	6.52	6.15
Weighted-Average Exercise Price Per Share, Ending Balance	3.07	2.97	$ 3.35
Weighted-Average Exercise Price Per Share, Vested and expected to vest	3.07
Weighted-Average Exercise Price Per Share, Exercisable	$ 2.91	$ 3.31
Weighted-Average Remaining Contractual Life, Outstanding	7 years 7 months 6 days	7 years 6 months	7 years 8 months 12 days
Weighted-Average Remaining Contractual Life, Vested and expected to vest	7 years 7 months 6 days
Weighted-Average Remaining Contractual Life, Exercisable	6 years 6 months	6 years 6 months
Aggregate Intrinsic Value, Balance	$ 366,007	$ 67,242	$ 36,887
Aggregate Intrinsic Value, Exercised	243,531	152,130
Aggregate Intrinsic Value, Vested and expected to vest	366,007
Aggregate Intrinsic Value, Exercisable	$ 346,595	$ 248

Stockholders Deficit - Summar_3

Stockholders Deficit - Summary of Material Factors Incorporated in Black-Scholes Model in Estimating Fair Value of Options Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	2.59%	1.75%
Risk-free interest rate, maximum	2.82%	2.20%
Expected volatility, minimum	79.50%	58.50%
Expected volatility, maximum	85.80%	62.60%
Expected dividend yield	0.00%	0.00%
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	1.88%	0.61%
Risk-free interest rate, maximum	2.07%	1.12%
Expected volatility, minimum	83.20%	68.00%
Expected volatility, maximum	85.80%	70.00%
Expected term	6 months	6 months
Expected dividend yield	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years 3 months 18 days	5 years 1 month 6 days
Minimum | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 3.26	$ 1.71
Minimum | Common Stock | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 1.85	$ 2.11
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years 6 months	6 years 3 months 18 days
Maximum | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 5.06	$ 3.46
Maximum | Common Stock | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 4	$ 3.17

Stockholders Deficit - Summar_4

Stockholders Deficit - Summary of Material Factors Incorporated in Black-Scholes Model in Estimating Fair Value of Options Granted (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)
Class Of Stock [Line Items]
Expected dividend assumed value	$ 0
2014 Employee Stock Purchase Plan
Class Of Stock [Line Items]
Expected dividend assumed value	$ 0

Stockholders Deficit - Summar_5

Stockholders Deficit - Summary of RSU Award Activity (Details) - Restricted Stock Units R S U - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Restricted Stock Units (RSU)
Beginning Balance	26,666	355,499
Granted	492,051	10,000
Vested		(336,333)
Forfeited		(2,500)
Ending Balance	227,707	26,666
Released	(291,010)
Vested and unissued at December 31, 2018	13,126
Weighted Average Grant Date Fair Value Per Share
Beginning Balance	$ 2.78	$ 2.41
Granted	3.63	1.75
Vested		2.47
Forfeited		2.46
Ending Balance	3.30	$ 2.78
Released	3.72
Vested and unissued at December 31, 2018	$ 3.40

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Feb. 29, 2016USD ($)
Commitments And Contingencies [Line Items]
Accrued employee bonuses	$ 2,150,418		$ 3,049,109
Lease expiration term	The Company leases office and laboratory space under two non-cancelable operating leases in Tucson, Arizona.	The Company leases office and laboratory space under two non-cancelable operating leases in Tucson, Arizona.
Lease extension term, in years	5 years
Expected increase in lease rent	$ 804,000
Leasehold improvements				$ 710,000	$ 710,000
Monthly accreted lease term as reduction of rent expense	11,833
Rent expense and common area maintenance costs under operating leases	583,182		570,979
Discretionary contributions company may make	0		0
Computer Equipment
Commitments And Contingencies [Line Items]
Capital lease commitments	$ 92,445
Computer Equipment | Minimum
Commitments And Contingencies [Line Items]
Capital lease commitment period	36 months	36 months
Computer Equipment | Maximum
Commitments And Contingencies [Line Items]
Capital lease commitment period	48 months	48 months
Capitalized Leasehold Improvements
Commitments And Contingencies [Line Items]
Depreciation	$ 142,000		142,000
HTG Molecular Diagnostics France SARL
Commitments And Contingencies [Line Items]
Lease, term of contract	9 years
Annual fixed lease payments | €		€ 8,200
Lease service charges | €		€ 1,200
Non-Executive Officer Employees
Commitments And Contingencies [Line Items]
Compensation expense	$ 881,336		358,744
Accrued employee bonuses	$ 635,377		$ 358,744

Commitments and Contingencies_2

Commitments and Contingencies - Minimum Facility Lease Payments Before Common Area Maintenance Charges (Details)	Dec. 31, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,019	$ 525,745
2,020	528,225
2,021	53,907
2,022	10,768
2,023	10,768
2024 and beyond	43,073
Total minimum lease payments	$ 1,172,486

Commitments and Contingencies_3

Commitments and Contingencies - Schedule Of Product Warranty Liability (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Beginning balance	$ 37,156	$ 50,426
Cost of warranty claims	(2,596)	(9,814)
Increase in warranty reserve	28,901	(3,456)
Ending balance	$ 63,461	$ 37,156

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Line Items]
Income tax examination, likelihood of unfavorable settlement	greater than 50 percent
Uncertain tax positions	$ 1,538,220	$ 0
Accrued interest or penalties	0	0
Recognized interest or penalties	$ 0	$ 0
U.S. federal corporate tax rate	21.00%	34.00%
Tax cuts and jobs act of 2017, change in tax rate, decrease in deferred tax assets	$ 16,232,211
Tax cuts and jobs act of 2017, change in tax rate, net adjustment in deferred tax expense	0
Valuation allowance	38,740,784	$ 35,008,331
Change in valuation reserve	3,732,453
Gross unrecognized tax benefits	1,538,220
Unrecognized tax benefits if recognized would impact effective tax rate	0
Research and Experimental Tax Credits
Income Tax Disclosure [Line Items]
Gross unrecognized tax benefits	1,538,220
Federal
Income Tax Disclosure [Line Items]
NOL carryforwards	138,759,835
State
Income Tax Disclosure [Line Items]
NOL carryforwards	89,208,791
France
Income Tax Disclosure [Line Items]
NOL carryforwards	$ 38,618
Beginning Expiration Year | Federal
Income Tax Disclosure [Line Items]
Tax credit carryforward, expiration year	2,021
Beginning Expiration Year | State
Income Tax Disclosure [Line Items]
Tax credit carryforward, expiration year	2,019
Maximum
Income Tax Disclosure [Line Items]
U.S. federal corporate tax rate		35.00%
Maximum | Federal
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2,038
Maximum | State
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2,038
Minimum | Federal
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2,021
Minimum | State
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2,027

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Current:
State	$ 3,526	$ 2,921
Total current income tax expense	3,526	2,921
Total income tax expense	$ 3,526	$ 2,921

Income Taxes - Difference in Ac

Income Taxes - Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Line Items]
Computed tax (benefit) at statutory rate (2018: 21%, 2017: 34%)	$ (3,454,582)	$ (6,445,413)
State taxes, net of federal benefit	(384,035)	(532,952)
Stock-based compensation	82,024	231,396
Foreign tax rate differential	(3,158)
Return to provision	(31,111)	(15,375)
Other	51,598	20,292
Federal rate change on deferred items as of enactment date		16,232,211
Uncertain tax position adjustment for prior periods	1,029,115
Increase (decrease) in valuation allowance	3,731,884	(8,470,655)
Total income tax expense	3,526	2,921
State
Income Tax Disclosure [Line Items]
Research and development tax credit	(511,845)	(576,525)
Federal
Income Tax Disclosure [Line Items]
Research and development tax credit	$ (506,364)	$ (440,058)

Income Taxes - Difference in _2

Income Taxes - Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	21.00%	34.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforwards	$ 33,431,082	$ 29,475,597
Research and development credits	3,076,441	3,114,091
Deferred revenue	86,567	204,061
Inventory reserve	9,645	15,134
Fixed assets and intangibles	223,767	147,395
Accrued liability	86,034	24,500
Other	106,913	74,986
Total deferred tax assets	38,740,784	35,008,331
Valuation allowance	(38,740,784)	(35,008,331)
NuvoGen
Deferred tax assets:
Accrued liability	$ 1,720,335	$ 1,952,567

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal Net Operating Loss Carryforwards (Details) - Federal	12 Months Ended
	Dec. 31, 2018USD ($)
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards	$ 138,759,835
2,021
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,021
Federal NOL carryforwards	$ 211,806
2,023
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,023
Federal NOL carryforwards	$ 1,635,651
2,024
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,024
Federal NOL carryforwards	$ 1,217,290
2,025
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,025
Federal NOL carryforwards	$ 1,409,498
2,026
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,026
Federal NOL carryforwards	$ 1,175,594
2,027
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,027
Federal NOL carryforwards	$ 1,676,458
2,028
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,028
Federal NOL carryforwards	$ 3,037,785
2,029
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,029
Federal NOL carryforwards	$ 3,753,314
2,030
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,030
Federal NOL carryforwards	$ 623,235
2,031
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,031
Federal NOL carryforwards	$ 5,435,312
2,032
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,032
Federal NOL carryforwards	$ 10,913,787
2,033
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,033
Federal NOL carryforwards	$ 12,095,966
2,034
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,034
Federal NOL carryforwards	$ 14,190,409
2,035
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,035
Federal NOL carryforwards	$ 21,112,183
2,036
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,036
Federal NOL carryforwards	$ 24,302,042
2,037
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,037
Federal NOL carryforwards	$ 18,986,265
2,038
Operating Loss Carryforwards [Line Items]
Federal NOL carryforwards, expiration year	2,038
Federal NOL carryforwards	$ 16,983,240

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Details)	12 Months Ended
	Dec. 31, 2018USD ($)
Income Tax Disclosure [Abstract]
Increases to prior positions	$ 1,029,115
Increases for current year positions	509,105
Balance at end of year	$ 1,538,220

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Nov. 17, 2016
Related Party Transaction [Line Items]
Service revenue		$ 21,503,894	$ 14,759,567
Research and development		12,598,034	9,996,627
Accounts receivable		5,012,678	6,356,268
Profit sharing payments included in collaborative development services revenue		$ 5,090,475	$ 4,971,806
Common stock, shares issued		28,585,449	13,929,763
Common stock value		$ 28,585	$ 13,929
Collaborative Development Services
Related Party Transaction [Line Items]
Service revenue		12,382,504	7,962,312
SOW One
Related Party Transaction [Line Items]
Profit sharing payments included in collaborative development services revenue		99,394	1,272,080
Research and development		1,716,115	2,129,138
Accounts receivable		0	2,429,152
SOW One | Collaborative Development Services
Related Party Transaction [Line Items]
Service revenue		2,297,742	2,604,892
SOW Two
Related Party Transaction [Line Items]
Profit sharing payments included in collaborative development services revenue		1,779,827	1,072,130
Research and development		3,625,332	2,645,825
Accounts receivable		1,007,950	1,796,157
Revenues		4,208,194	2,988,211
SOW Two | Collaborative Development Services
Related Party Transaction [Line Items]
Service revenue		5,988,021	4,060,341
SOW Three
Related Party Transaction [Line Items]
Research and development		2,667,030
Accounts receivable		363,869	0
Revenues		3,641,715	0
Profit sharing payments included in collaborative development services revenue		355,631	0
SOW Three | Collaborative Development Services
Related Party Transaction [Line Items]
Service revenue		$ 3,997,346
QIAGEN Manchester Limited
Related Party Transaction [Line Items]
Agreement commencement period		2016-11
Term of agreement		5 years
Termination payment		$ 2,000,000
QIAGEN Manchester Limited | Maximum
Related Party Transaction [Line Items]
Term of agreement		1 year
QIAGEN North American Holdings, Inc.
Related Party Transaction [Line Items]
Revenues		$ 35,000	4,375
Common stock, shares issued				833,333
Common stock value				$ 2,000,000
Deferred revenue		$ 175,000
Deferred revenue recognition period		5 years
QIAGEN North American Holdings, Inc. | Convertible Promissory Note
Related Party Transaction [Line Items]
Cash proceeds from issuance of subordinated notes	$ 3,000,000
Debt instrument, interest rate	3.00%
Debt instrument, maturity date	Oct. 26, 2020
Conversion price per share	$ 3.984
Debt issuance costs		$ 25,787	40,510
QIAGEN North American Holdings, Inc. | Convertible Promissory Note | Interest Expense
Related Party Transaction [Line Items]
Amortization of deferred financing costs		13,454	1,269
Interest accrued		$ 90,000	$ 8,630
QIAGEN North American Holdings, Inc. | Common Stock
Related Party Transaction [Line Items]
Shares issued price per share				$ 2.40